RGD DISEASE ONTOLOGY - ANNOTATIONS |
|
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
|
Term: | Neoplastic Processes |
|
Accession: | DOID:9008192
|
browse the term
|
Definition: | The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity. |
Synonyms: | primary_id: | MESH:D009385 |
|
|
|
G |
Chaf1b |
chromatin assembly factor 1, subunit B |
|
ISO |
protein:increased expression:: |
RGD |
PMID:22882088 |
RGD:9587477 |
NCBI chr16:93,680,801...93,703,003
Ensembl chr16:93,680,789...93,703,003
|
|
G |
Erg |
ETS transcription factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chr16:95,160,028...95,387,452
Ensembl chr16:95,160,028...95,387,452
|
|
G |
Etv1 |
ets variant 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chr12:38,829,655...38,920,484
Ensembl chr12:38,829,379...38,920,483
|
|
G |
Etv4 |
ets variant 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chr11:101,660,573...101,677,963
Ensembl chr11:101,660,568...101,676,197
|
|
G |
Etv5 |
ets variant 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chr16:22,200,063...22,258,320
Ensembl chr16:22,200,059...22,258,469
|
|
G |
Ewsr1 |
Ewing sarcoma breakpoint region 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266
|
|
G |
Hdlbp |
high density lipoprotein (HDL) binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25129143 |
|
NCBI chr 1:93,333,662...93,406,639
Ensembl chr 1:93,333,662...93,406,537
|
|
G |
Hoxd9 |
homeobox D9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26075790 |
|
NCBI chr 2:74,528,107...74,530,552
Ensembl chr 2:74,528,071...74,530,552
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12082015 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
|
G |
Car9 |
carbonic anhydrase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
|
G |
Aicda |
activation-induced cytidine deaminase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chr 6:122,530,768...122,541,139
Ensembl chr 6:122,530,760...122,541,139
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chr10:74,896,384...75,020,753
Ensembl chr10:74,896,424...75,020,753
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
|
IMP |
|
RGD |
PMID:12740446 |
RGD:734951 |
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
|
RGD |
PMID:22139798 |
RGD:10755566 |
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Mir150 |
microRNA 150 |
|
ISO |
miRNA:decreased expression:leukocytes |
RGD |
PMID:21501493 |
RGD:13782140 |
NCBI chr 7:44,771,181...44,771,245
Ensembl chr 7:44,771,181...44,771,245
|
|
G |
Tcn2 |
transcobalamin 2 |
|
ISO |
protein:increased expression:: |
RGD |
PMID:1059479 |
RGD:11060122 |
NCBI chr11:3,867,077...3,882,078
Ensembl chr11:3,867,192...3,882,159
|
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase |
|
ISO |
associated with Prostatic Neoplasms; |
RGD |
PMID:14669797 |
RGD:1578303 |
NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179
|
|
G |
Brip1 |
BRCA1 interacting protein C-terminal helicase 1 |
|
ISO |
associated with Breast Neoplasms; human gene in a mouse model |
RGD |
PMID:22875853 |
RGD:11252149 |
NCBI chr11:85,948,957...86,092,041
Ensembl chr11:85,948,964...86,092,019
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
disease_progression |
ISO |
associated with hepatocellular carcinoma;protein:increased expression:liver (human) |
RGD |
PMID:19508713 |
RGD:152023653 |
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:bone element (human) |
RGD |
PMID:23861746 |
RGD:13204736 |
NCBI chr10:24,513,812...24,588,057
Ensembl chr10:24,513,812...24,588,057
|
|
G |
Mir34a |
microRNA 34a |
susceptibility |
ISO |
associated with hepatocellular carcinoma;miRNA:decreased expression:serum, bone |
RGD |
PMID:27893432 |
RGD:14694837 |
NCBI chr 4:150,152,911...150,153,012
Ensembl chr 4:150,152,911...150,153,012
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
|
ISO |
associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human) |
RGD |
PMID:18709334 |
RGD:2306080 |
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Pdgfd |
platelet-derived growth factor, D polypeptide |
|
ISO |
associated with prostate carcinoma |
RGD |
PMID:22158043 |
RGD:13506772 |
NCBI chr 9:6,168,377...6,534,284
Ensembl chr 9:6,168,584...6,378,850
|
|
|
G |
Abl1 |
c-abl oncogene 1, non-receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23968727 |
|
NCBI chr 2:31,578,256...31,697,105
Ensembl chr 2:31,578,388...31,694,239
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
|
IMP |
|
RGD |
PMID:21697277 |
RGD:13838723 |
NCBI chr16:38,265,761...38,273,051
Ensembl chr16:38,264,392...38,273,065
|
|
G |
Akr1a1 |
aldo-keto reductase family 1, member A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32805337 |
|
NCBI chr 4:116,493,707...116,508,871
Ensembl chr 4:116,493,707...116,508,877
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Braf |
Braf transforming gene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24717435 |
|
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29247004 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21526190 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cux1 |
cut-like homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24316979 |
|
NCBI chr 5:136,276,989...136,596,429
Ensembl chr 5:136,276,989...136,596,344
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25221644 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Gata3 |
GATA binding protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35115686 |
|
NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845
|
|
G |
Gm57540 |
predicted gene, 57540 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26595770 |
|
NCBI chr 9:88,957,389...88,957,460
Ensembl chr 9:88,957,389...88,957,460
|
|
G |
H19 |
H19, imprinted maternally expressed transcript |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32739445 |
|
NCBI chr 7:142,129,267...142,131,883
Ensembl chr 7:142,129,262...142,131,917
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26595770 PMID:29247004 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,852,706
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
|
ISO IMP |
|
RGD |
PMID:15287022 PMID:23533274 |
RGD:151356924, RGD:151356978 |
NCBI chr18:4,331,325...4,352,978
Ensembl chr18:4,331,327...4,353,015
|
|
G |
Met |
met proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979
|
|
G |
Mir143 |
microRNA 143 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:28736328 |
|
NCBI chr18:61,782,267...61,782,329
Ensembl chr18:61,782,267...61,782,329
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29228771 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24487275 |
|
NCBI chr11:74,564,775...74,615,210
Ensembl chr11:74,564,775...74,615,496
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Sparc |
secreted acidic cysteine rich glycoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26783756 |
|
NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
|
|
G |
Tnfsf8 |
tumor necrosis factor (ligand) superfamily, member 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:11552987 |
|
NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584
|
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29044505 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
|
G |
Ace |
angiotensin I converting enzyme |
|
IEP |
associated with colorectal cancer;mRNA:increased expression:liver (mouse) |
RGD |
PMID:20380732 |
RGD:25671446 |
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Braf |
Braf transforming gene |
severity |
IAGP |
associated with colorectal cancer;DNA:mutation:cds: associated with colorectal cancer;DNA:mutations:multiple associated with skin melanoma;DNA:missense mutations:cds: associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human) associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human) |
RGD |
PMID:27737491 PMID:26775732 PMID:28787433 PMID:22331825 PMID:23010994 |
RGD:18337264, RGD:11554843, RGD:14696791, RGD:18337265, RGD:15039394 |
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
disease_progression |
ISO |
associated with colorectal cancer |
RGD |
PMID:27058904 |
RGD:14995463 |
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
IMP |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccng1 |
cyclin G1 |
treatment |
ISO |
human cells in mouse model |
RGD |
PMID:10910035 |
RGD:151356987 |
NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138
|
|
G |
Cd44 |
CD44 antigen |
|
ISO |
associated with Breast Neoplasm;protein:increased expression:liver |
RGD |
PMID:17991717 |
RGD:2289349 |
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chr 6:125,073,144...125,107,554
Ensembl chr 6:125,072,944...125,107,554
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
treatment |
IDA |
associated with colon carcinoma; |
RGD |
PMID:30381616 |
RGD:27095891 |
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
|
ISO |
associated with colorectal cancer; human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:29679563 |
RGD:26884358 |
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model human cells in mouse model; associated with colorectal cancer |
RGD |
PMID:30789971 PMID:29436696 |
RGD:151893289, RGD:152023643 |
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Daxx |
Fas death domain-associated protein |
exacerbates |
ISO |
associated with colon cancer; mRNA:decreased expression:liver (human) associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human) associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human) |
RGD |
PMID:31942198 PMID:30339629 PMID:30342802 |
RGD:152025194, RGD:152025203, RGD:152025199 |
NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564
|
|
G |
Ddr1 |
discoidin domain receptor family, member 1 |
treatment |
IMP IEP ISO |
mRNA:increased expression:liver (mouse) human cells in mouse model; nilotinib |
RGD |
PMID:33110221 PMID:30666650 PMID:29438985 |
RGD:151347537, RGD:151347840, RGD:151347685 |
NCBI chr17:35,992,459...36,015,633
Ensembl chr17:35,992,459...36,015,513
|
|
G |
Ddr2 |
discoidin domain receptor family, member 2 |
ameliorates |
IMP ISO |
associated with colon carcinoma associated with melanoma; |
RGD |
PMID:22071959 PMID:21701781 |
RGD:150429701, RGD:150429713 |
NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331
|
|
G |
Dock6 |
dedicator of cytokinesis 6 |
ameliorates |
ISO |
associated with stomach cancer; |
RGD |
PMID:29587866 |
RGD:155791564 |
NCBI chr 9:21,711,476...21,764,006
Ensembl chr 9:21,711,156...21,763,931
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
disease_progression |
ISO |
associated with colorectal cancer; |
RGD |
PMID:28846828 |
RGD:21408566 |
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
ISO |
associated with colorectal cancer;mRNA:increased expression:colorectal mucosa: |
RGD |
PMID:19082464 |
RGD:25330357 |
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fosl2 |
fos-like antigen 2 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30114390 |
RGD:153344554 |
NCBI chr 5:32,292,599...32,315,184
Ensembl chr 5:32,293,145...32,315,186
|
|
G |
Gpc3 |
glypican 3 |
|
ISO |
protein:increased expression:blood serum (human) |
RGD |
PMID:28801286 |
RGD:243065135 |
NCBI chr X:51,361,303...51,702,851
Ensembl chr X:51,361,303...51,702,827
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
|
ISO |
associated with colon adenocarcinoma;protein:decreased activity:liver(rat) |
RGD |
PMID:1386052 |
RGD:25440496 |
NCBI chr 9:44,247,645...44,255,525
Ensembl chr 9:44,247,636...44,255,525
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with Colorectal Neoplasms, Carcinoma, Hepatocellular; associated with colon carcinoma |
RGD |
PMID:11591892 PMID:9354462 |
RGD:8663446, RGD:14928215 |
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:22662237 |
RGD:153344589 |
NCBI chr 6:90,636,578...90,965,766
Ensembl chr 6:90,633,070...90,965,667
|
|
G |
Map2k7 |
mitogen-activated protein kinase kinase 7 |
|
ISO |
associated with colon cancer;protein:increased expression:colon (human) |
RGD |
PMID:24533778 |
RGD:155259116 |
NCBI chr 8:4,288,740...4,297,897
Ensembl chr 8:4,288,740...4,297,897 Ensembl chr 8:4,288,740...4,297,897
|
|
G |
Mir141 |
microRNA 141 |
|
ISO |
associated with colorectal cancer;RNA:increased expression:liver: |
RGD |
PMID:28617555 |
RGD:14928321 |
NCBI chr 6:124,694,877...124,694,948
Ensembl chr 6:124,694,877...124,694,948
|
|
G |
Mir148b |
microRNA 148b |
exacerbates |
ISO |
associated with stomach cancer; |
RGD |
PMID:29587866 |
RGD:155791564 |
NCBI chr15:103,193,552...103,193,648
Ensembl chr15:103,193,552...103,193,648
|
|
G |
Mir155 |
microRNA 155 |
|
ISO |
|
RGD |
PMID:26885061 |
RGD:21079444 |
NCBI chr16:84,511,028...84,511,092
Ensembl chr16:84,511,028...84,511,092
|
|
G |
Mir200b |
microRNA 200b |
|
ISO |
associated with colorectal cancer;RNA:increased expression:liver: |
RGD |
PMID:28617555 |
RGD:14928321 |
NCBI chr 4:156,140,138...156,140,207
Ensembl chr 4:156,140,138...156,140,207
|
|
G |
Mir200c |
microRNA 200c |
|
ISO |
associated with colorectal cancer;RNA:increased expression:liver: |
RGD |
PMID:28617555 |
RGD:14928321 |
NCBI chr 6:124,695,285...124,695,353
Ensembl chr 6:124,695,285...124,695,353
|
|
G |
Mir223 |
microRNA 223 |
disease_progression |
ISO |
associated with colorectal cancer; |
RGD |
PMID:28846828 |
RGD:21408566 |
NCBI chr X:95,286,423...95,286,532
Ensembl chr X:95,286,423...95,286,532
|
|
G |
Mir494 |
microRNA 494 |
exacerbates |
ISO |
associated with pancreatic ductal adenocarcinoma; |
RGD |
PMID:24859161 |
RGD:156430321 |
NCBI chr12:109,681,752...109,681,836
Ensembl chr12:109,681,752...109,681,836
|
|
G |
Mpl |
myeloproliferative leukemia virus oncogene |
severity exacerbates |
IMP ISO |
associated with pancreatic ductal adenocarcinoma; human cells in mouse model associated with colorectal carcinoma;protein:increased expression:colorectum (human) associated with pancreatic cancer; protein:increased expression:liver, pancreas (human) |
RGD |
PMID:30770989 PMID:23747337 PMID:30770989 |
RGD:126925751, RGD:126925752, RGD:126925751 |
NCBI chr 4:118,299,609...118,314,771
Ensembl chr 4:118,299,612...118,314,710
|
|
G |
Nras |
neuroblastoma ras oncogene |
susceptibility |
ISO |
human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human) associated with colorectal cancer;DNA:mutations:exons (human) associated with melanoma;DNA:mutations: exons (human) |
RGD |
PMID:26799184 PMID:28011498 PMID:28787433 |
RGD:14696774, RGD:14696792, RGD:14696791 |
NCBI chr 3:102,965,643...102,975,230
Ensembl chr 3:102,965,601...102,975,230
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
IMP |
mouse tumor cells in mouse recipient |
RGD |
PMID:31348125 |
RGD:151660353 |
NCBI chr10:116,111,407...116,225,443
Ensembl chr10:116,111,428...116,225,440
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
disease_progression |
IMP ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:30404068 PMID:30404068 |
RGD:152995463, RGD:152995463 |
NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882
|
|
G |
Rnf43 |
ring finger protein 43 |
|
ISO |
associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human) |
RGD |
PMID:28789449 |
RGD:151361221 |
NCBI chr11:87,553,913...87,626,365
Ensembl chr11:87,553,548...87,626,365
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
severity |
ISO |
associated with colon adenocarcinoma |
RGD |
PMID:11745822 |
RGD:151361130 |
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc7a5 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 |
severity |
ISO |
associated with colon cancer associated with colon adenocarcinoma |
RGD |
PMID:11718450 PMID:11745822 |
RGD:151361129, RGD:151361130 |
NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433
|
|
G |
Smad4 |
SMAD family member 4 |
treatment |
ISO |
associated with colorectal carcinoma; DNA:mutations: : associated with colorectal carcinoma;protein:decreased expression:colorectum: |
RGD |
PMID:29551247 PMID:17390050 |
RGD:18937000, RGD:21066338 |
NCBI chr18:73,767,861...73,836,862
Ensembl chr18:73,772,080...73,836,851
|
|
G |
Sox30 |
SRY (sex determining region Y)-box 30 |
ameliorates |
IDA |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chr11:45,869,873...45,908,824
Ensembl chr11:45,871,137...45,908,821
|
|
G |
Src |
Rous sarcoma oncogene |
disease_progression |
ISO |
associated with colon cancer;protein:increased activity:colon |
RGD |
PMID:7678609 |
RGD:150521542 |
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO |
associated with colorectal carcinoma;mRNA,protein:increased expression:liver: |
RGD |
PMID:22156924 |
RGD:15014782 |
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
Adam28 |
a disintegrin and metallopeptidase domain 28 |
ameliorates |
ISO |
associated with lung carcinoma, breast carcinoma associated with lung adenocarcinoma; |
RGD |
PMID:22636800 PMID:26800504 |
RGD:153297785, RGD:11531771 |
NCBI chr14:68,842,447...68,893,338
Ensembl chr14:68,843,476...68,893,291
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
IMP |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:20860838 |
RGD:126848767 |
NCBI chr12:52,550,555...52,618,761
Ensembl chr12:52,550,755...52,618,758
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
exacerbates |
ISO |
associated with hepatocellular carcinoma, |
RGD |
PMID:32071245 |
RGD:150340708 |
NCBI chr15:96,185,403...96,303,344
Ensembl chr15:96,185,399...96,302,873
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc |
ameliorates |
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:27993894 PMID:26902423 |
RGD:153350132, RGD:153350133 |
NCBI chr 5:137,979,783...137,988,495
Ensembl chr 5:137,979,782...137,988,495
|
|
G |
Car12 |
carbonic anhydrase 12 |
ameliorates |
ISO |
associated with breast cancer; |
RGD |
PMID:29786141 |
RGD:155226861 |
NCBI chr 9:66,619,026...66,674,127
Ensembl chr 9:66,620,968...66,674,127
|
|
G |
Cblb |
Casitas B-lineage lymphoma b |
severity |
ISO |
associated with stomach carcinoma; |
RGD |
PMID:28334634 |
RGD:150540337 |
NCBI chr16:51,851,593...52,028,410
Ensembl chr16:51,851,588...52,028,411
|
|
G |
Ccng1 |
cyclin G1 |
|
IMP |
|
RGD |
PMID:30565428 |
RGD:151361205 |
NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chr 6:125,073,144...125,107,554
Ensembl chr 6:125,072,944...125,107,554
|
|
G |
Col10a1 |
collagen, type X, alpha 1 |
ameliorates |
ISO |
associated with H1299 cell |
RGD |
PMID:33324550 |
RGD:150429752 |
NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO IMP |
associated with colorectal cancer; human cells in mouse model associated with nasopharynx carcinoma; human cells in mouse model associated with osteosarcoma and melanoma |
RGD |
PMID:31938138 PMID:16000558 PMID:26498029 PMID:18071913 |
RGD:151665329, RGD:151893515, RGD:152023752, RGD:152177473 |
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Ddr1 |
discoidin domain receptor family, member 1 |
|
IMP |
|
RGD |
PMID:29483153 |
RGD:151347599 |
NCBI chr17:35,992,459...36,015,633
Ensembl chr17:35,992,459...36,015,513
|
|
G |
Ddr2 |
discoidin domain receptor family, member 2 |
exacerbates |
ISO |
associated with tongue squamous cell carcinoma; |
RGD |
PMID:24556606 |
RGD:150429746 |
NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331
|
|
G |
Fasn |
fatty acid synthase |
|
ISO |
associated with head and neck squamous cell carcinoma |
RGD |
PMID:20604875 |
RGD:126790467 |
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fosl2 |
fos-like antigen 2 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30326930 |
RGD:153344557 |
NCBI chr 5:32,292,599...32,315,184
Ensembl chr 5:32,293,145...32,315,186
|
|
G |
Hilpda |
hypoxia inducible lipid droplet associated |
|
ISO |
human cells in mouse model |
RGD |
PMID:31142329 |
RGD:153344574 |
NCBI chr 6:29,272,487...29,275,448
Ensembl chr 6:29,272,487...29,275,445
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:18084281 |
RGD:153344604 |
NCBI chr 6:90,636,578...90,965,766
Ensembl chr 6:90,633,070...90,965,667
|
|
G |
Itgav |
integrin alpha V |
treatment |
ISO |
human cells in rat model |
RGD |
PMID:20841470 |
RGD:152998949 |
NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
ameliorates |
IMP |
associated with breast carcinoma |
RGD |
PMID:16568086 |
RGD:150573808 |
NCBI chr13:111,882,962...111,954,803
Ensembl chr13:111,882,962...111,945,527
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
ameliorates |
ISO |
associated with clear cell renal cell carcinoma |
RGD |
PMID:23982215 |
RGD:151356974 |
NCBI chr18:4,331,325...4,352,978
Ensembl chr18:4,331,327...4,353,015
|
|
G |
Mir423 |
microRNA 423 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30326930 |
RGD:153344557 |
NCBI chr11:76,968,890...76,968,998
Ensembl chr11:76,968,890...76,968,998
|
|
G |
Mir494 |
microRNA 494 |
ameliorates |
ISO |
associated with hepatocellular carcinoma |
RGD |
PMID:25820676 PMID:28055013 |
RGD:155900754, RGD:156430322 |
NCBI chr12:109,681,752...109,681,836
Ensembl chr12:109,681,752...109,681,836
|
|
G |
Mir744 |
microRNA 744 |
treatment |
ISO |
associated with nasopharynx carcinoma |
RGD |
PMID:25961434 |
RGD:11056278 |
NCBI chr11:65,625,559...65,625,658
Ensembl chr11:65,625,559...65,625,658
|
|
G |
Nf2 |
neurofibromin 2 |
|
ISO |
associated with hepatocellular carcinoma |
RGD |
PMID:26443326 |
RGD:11076529 |
NCBI chr11:4,715,845...4,799,544
Ensembl chr11:4,715,845...4,799,536
|
|
G |
Ntrk3 |
neurotrophic tyrosine kinase, receptor, type 3 |
ameliorates |
IMP |
associated with mammary carcinoma |
RGD |
PMID:20802235 |
RGD:150520014 |
NCBI chr 7:77,825,711...78,228,865
Ensembl chr 7:77,825,707...78,387,760
|
|
G |
Pagr1a |
PAXIP1 associated glutamate rich protein 1A |
|
ISO |
human cells in mouse model |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chr 7:126,614,223...126,616,524
Ensembl chr 7:126,614,205...126,616,524 Ensembl chr 7:126,614,205...126,616,524
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
IMP |
|
RGD |
PMID:23899555 |
RGD:151660352 |
NCBI chr10:116,111,407...116,225,443
Ensembl chr10:116,111,428...116,225,440
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
|
ISO IMP |
human cells in mouse model |
RGD |
PMID:20978191 PMID:29809146 |
RGD:152995469, RGD:152995516 |
NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
|
IMP |
|
RGD |
PMID:29809146 |
RGD:152995516 |
NCBI chr11:119,493,731...119,790,417
Ensembl chr11:119,493,731...119,790,402
|
|
G |
Sf3b4 |
splicing factor 3b, subunit 4 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30391496 |
RGD:155804298 |
NCBI chr 3:96,079,822...96,084,880
Ensembl chr 3:96,079,648...96,084,880
|
|
G |
Sox30 |
SRY (sex determining region Y)-box 30 |
ameliorates |
IDA |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chr11:45,869,873...45,908,824
Ensembl chr11:45,871,137...45,908,821
|
|
G |
Src |
Rous sarcoma oncogene |
treatment ameliorates |
ISO |
associated with breast cancer; associated with nasopharynx carcinoma; |
RGD |
PMID:15753384 PMID:27078847 |
RGD:1581400, RGD:150521726 |
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
|
G |
Abca13 |
ATP-binding cassette, sub-family A member 13 |
susceptibility |
ISO |
DNA:amplification:cds: (human, male) |
RGD |
PMID:27366209 |
RGD:152995256 |
NCBI chr11:9,141,942...9,634,871
Ensembl chr11:9,141,942...9,634,259
|
|
G |
Adam28 |
a disintegrin and metallopeptidase domain 28 |
|
ISO |
associated with breast cancer;DNA:hypermethylation: |
RGD |
PMID:25620615 |
RGD:153298970 |
NCBI chr14:68,842,447...68,893,338
Ensembl chr14:68,843,476...68,893,291
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
disease_progression |
ISO |
associated with stomach cancer; |
RGD |
PMID:11172604 |
RGD:13831357 |
NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314
|
|
G |
Aicda |
activation-induced cytidine deaminase |
|
ISO |
associated with stomach cancer;protein:increased expression:stomach (human) |
RGD |
PMID:21538122 |
RGD:127285638 |
NCBI chr 6:122,530,768...122,541,139
Ensembl chr 6:122,530,760...122,541,139
|
|
G |
Angptl4 |
angiopoietin-like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Aqp3 |
aquaporin 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21401805 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
ISO |
associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx |
RGD |
PMID:25961434 |
RGD:11056278 |
NCBI chr12:52,550,555...52,618,761
Ensembl chr12:52,550,755...52,618,758
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:32317519 |
RGD:126779580 |
NCBI chr 2:153,187,750...153,245,927
Ensembl chr 2:153,187,749...153,245,927
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
associated Pancreatic Neoplasms |
RGD |
PMID:19252414 |
RGD:2325833 |
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
Bag1 |
BCL2-associated athanogene 1 |
disease_progression |
ISO |
associated with Breast Neoplasms:protein:increased expression:breast |
RGD |
PMID:18430249 |
RGD:2292908 |
NCBI chr 4:40,936,398...40,948,294
Ensembl chr 4:40,936,398...40,948,294
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
|
ISO |
associated with stomach cancer; protein:increased expression: : |
RGD |
PMID:24752577 |
RGD:14390158 |
NCBI chr18:3,507,011...3,516,404
Ensembl chr18:3,507,923...3,516,404
|
|
G |
Barhl2 |
BarH like homeobox 2 |
|
ISO |
associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucous |
RGD |
PMID:27542258 |
RGD:14390167 |
NCBI chr 5:106,600,389...106,606,032
Ensembl chr 5:106,600,389...106,606,032
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:lymph node |
RGD |
PMID:18217456 |
RGD:2293013 |
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bik |
BCL2-interacting killer |
|
ISO |
associated with cholangiocarcinoma;DNA:CNV:: |
RGD |
PMID:16865775 |
RGD:14394820 |
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
disease_progression |
ISO |
associated with Cervix Neoplasms;mRNA:splice variant associated with Breast Neoplasms |
RGD |
PMID:17877643 PMID:17285241 |
RGD:2293098, RGD:2293103 |
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Braf |
Braf transforming gene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
|
|
G |
Brd7 |
bromodomain containing 7 |
severity |
ISO |
protein:increased expression:lung: |
RGD |
PMID:22008115 |
RGD:9586442 |
NCBI chr 8:89,056,522...89,089,249
Ensembl chr 8:89,057,667...89,088,822
|
|
G |
Bsg |
basigin |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16004819 |
RGD:2289055 |
NCBI chr10:79,540,192...79,547,813
Ensembl chr10:79,540,325...79,547,803
|
|
G |
Btk |
Bruton agammaglobulinemia tyrosine kinase |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:lung (human) |
RGD |
PMID:31200752 |
RGD:151347847 |
NCBI chr X:133,443,083...133,484,366
Ensembl chr X:133,443,085...133,484,319
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with pancreatic cancer;RNA:increased expression:pancreas |
RGD |
PMID:28197410 |
RGD:14398834 |
NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297
|
|
G |
Car9 |
carbonic anhydrase 9 |
|
ISO |
associated with Cervix Neoplasms |
RGD |
PMID:17233814 |
RGD:2293196 |
NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729
|
|
G |
Casp9 |
caspase 9 |
|
ISO |
associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human) |
RGD |
PMID:17285546 |
RGD:13434907 |
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
disease_progression |
ISO |
associated with Melanoma |
RGD |
PMID:22134245 |
RGD:8661767 |
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cbl |
Casitas B-lineage lymphoma |
|
ISO |
associated with stomach carcinoma;protein:increased expression:stomach |
RGD |
PMID:31611438 |
RGD:126925223 |
NCBI chr 9:44,054,273...44,145,556
Ensembl chr 9:44,054,273...44,145,346
|
|
G |
Cblb |
Casitas B-lineage lymphoma b |
|
ISO |
associated with stomach carcinoma; |
RGD |
PMID:20038312 |
RGD:150540338 |
NCBI chr16:51,851,593...52,028,410
Ensembl chr16:51,851,588...52,028,411
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccne1 |
cyclin E1 |
|
ISO |
associated with Carcinoma, Transitional Cell;protein:decreased expression |
RGD |
PMID:16949911 |
RGD:2289266 |
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Ccnh |
cyclin H |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr13:85,337,504...85,361,850
Ensembl chr13:85,337,527...85,371,588
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:24301790 |
RGD:8551816 |
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Cd274 |
CD274 antigen |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16530813 |
|
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd40 |
CD40 antigen |
|
ISO |
associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human) |
RGD |
PMID:21912605 |
RGD:8547780 |
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd44 |
CD44 antigen |
|
ISO |
associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach |
RGD |
PMID:16425351 |
RGD:2289356 |
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:18097581 PMID:17649807 |
RGD:2296046, RGD:2289498 |
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Eyelid Neoplasms; associated with Oral Squamous Cell Carcinoma; |
RGD |
PMID:19628749 PMID:15817070 |
RGD:8661799, RGD:8662374 |
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
|
ISO |
associated with Breast Neoplasms associated with non-small cell lung carcinoma |
RGD |
PMID:12015771 PMID:28601655 |
RGD:2293607, RGD:13673921 |
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cldn1 |
claudin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:33665778 |
|
NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591
|
|
G |
Clptm1l |
CLPTM1-like |
|
ISO |
associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus |
RGD |
PMID:25480402 |
RGD:150530497 |
NCBI chr13:73,752,121...73,768,758
Ensembl chr13:73,752,125...73,768,724
|
|
G |
Clu |
clusterin |
|
ISO |
associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human) |
RGD |
PMID:22037783 |
RGD:8963167 |
NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
|
|
G |
Comt |
catechol-O-methyltransferase |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human) |
RGD |
PMID:10755383 |
RGD:8662330 |
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
susceptibility |
ISO |
associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human) |
RGD |
PMID:24633920 |
RGD:9580226 |
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:14734466 |
RGD:2293711 |
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
|
IMP |
associated with Prostatic Neoplasms |
RGD |
PMID:10611340 |
RGD:4891523 |
NCBI chr 1:60,948,184...60,954,991
Ensembl chr 1:60,926,159...60,954,991
|
|
G |
Ctnna1 |
catenin alpha 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:12047765 |
RGD:2289795 |
NCBI chr18:35,251,955...35,387,829
Ensembl chr18:35,251,912...35,387,832
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:17908479 |
RGD:2289813 |
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
disease_progression |
ISO |
associated with stomach cancer;mRNA:increased expression:stomach (human) |
RGD |
PMID:21633638 |
RGD:152023624 |
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
associated with nasopharynx carcinoma; protein:increased expression:lymph node (human) |
RGD |
PMID:16000558 |
RGD:151893515 |
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cycs |
cytochrome c, somatic |
|
ISO |
associated with non-small cell lung carcinoma; protein:decreased expression:serum |
RGD |
PMID:25578497 |
RGD:13792769 |
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Ddr1 |
discoidin domain receptor family, member 1 |
severity |
ISO |
mRNA, protein:increased expression:mouth (human) mRNA:increased expression:kidney, lymph nodes (human) |
RGD |
PMID:31253192 PMID:27020590 |
RGD:151347620, RGD:151347863 |
NCBI chr17:35,992,459...36,015,633
Ensembl chr17:35,992,459...36,015,513
|
|
G |
Ddr2 |
discoidin domain receptor family, member 2 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma |
RGD |
PMID:29945346 |
RGD:150429700 |
NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
|
ISO |
associated with Carcinoma, Pancreatic Ductal; |
RGD |
PMID:22919364 |
RGD:9589121 |
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
Ebag9 |
estrogen receptor-binding fragment-associated gene 9 |
|
ISO |
associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node associated with Breast Neoplasms;protein:increased expression:breast |
RGD |
PMID:12845666 PMID:12054692 PMID:17187007 |
RGD:2289856, RGD:2298489, RGD:2289847 |
NCBI chr15:44,482,574...44,504,916
Ensembl chr15:44,482,571...44,504,911
|
|
G |
Egfr |
epidermal growth factor receptor |
treatment |
IMP |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Ehmt2 |
euchromatic histone lysine N-methyltransferase 2 |
|
ISO |
associated with Melanoma; associated with Esophageal Squamous Cell Carcinoma; |
RGD |
PMID:24658378 PMID:24805087 |
RGD:9590069, RGD:9590071 |
NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028
|
|
G |
Epha2 |
Eph receptor A2 |
|
ISO |
protein:increased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chr 4:141,028,532...141,056,695
Ensembl chr 4:141,028,551...141,056,695
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
disease_progression |
ISO |
associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V associated with lung adenocarcinoma; protein:increased expression:lung (human) CTD Direct Evidence: marker/mechanism associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder |
RGD CTD |
PMID:21532492 PMID:21966491 PMID:18237248 PMID:18097576 |
RGD:153344600, RGD:2289925, RGD:2289926 |
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
|
ISO |
associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus associated with head and neck squamous cell carcinoma |
RGD |
PMID:17634423 PMID:20604875 |
RGD:2289944, RGD:126790467 |
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
disease_progression severity |
ISO |
associated with oral squamous cell carcinoma associated with lung non-small cell carcinoma associated with colorectal adenocarcinoma |
RGD |
PMID:27444519 PMID:21324275 PMID:16507107 |
RGD:126781762, RGD:126790471, RGD:126781766 |
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Fas |
Fas cell surface death receptor |
susceptibility |
ISO |
associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A |
RGD |
PMID:18068525 |
RGD:2298509 |
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
|
ISO |
associated with Cervix Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17242701 |
RGD:2290286 |
NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
ISO |
associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human) |
RGD |
PMID:20640597 |
RGD:7394846 |
NCBI chr 7:129,764,181...129,868,538
Ensembl chr 7:129,764,181...132,725,079
|
|
G |
Flt3 |
FMS-like tyrosine kinase 3 |
disease_progression |
IMP |
associated with Prostatic Neoplasms |
RGD |
PMID:14566827 |
RGD:2302210 |
NCBI chr 5:147,267,551...147,337,299
Ensembl chr 5:147,267,551...147,337,299
|
|
G |
Foxa1 |
forkhead box A1 |
|
ISO |
associated with lung non-small cell carcinoma; mRNA:increased expression: : |
RGD |
PMID:29115441 |
RGD:151665751 |
NCBI chr12:57,585,750...57,594,815
Ensembl chr12:57,587,414...57,593,702
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chr 6:98,902,303...99,510,587
Ensembl chr 6:98,902,299...99,499,682
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
|
ISO |
associated with stomach carcinoma; DNA:hypermethylation:promoter |
RGD |
PMID:23071548 |
RGD:151665353 |
NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
|
|
G |
Grik2 |
glutamate receptor, ionotropic, kainate 2 (beta 2) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr10:48,969,776...49,666,523
Ensembl chr10:48,970,929...49,664,862
|
|
G |
Hmgb1 |
high mobility group box 1 |
|
ISO |
associated with Adenocarcinoma, Colon |
RGD |
PMID:20616616 |
RGD:10402080 |
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:21590495 |
RGD:8547712 |
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ier2 |
immediate early response 2 |
|
ISO |
|
RGD |
PMID:22120713 |
RGD:153323322 |
NCBI chr 8:85,387,960...85,389,481
Ensembl chr 8:85,387,960...85,389,483
|
|
G |
Il13 |
interleukin 13 |
|
ISO |
associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node |
RGD |
PMID:17545514 |
RGD:8549587 |
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:12902898 |
RGD:8655867 |
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Ing4 |
inhibitor of growth family, member 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27806345 |
|
NCBI chr 6:125,016,811...125,026,228
Ensembl chr 6:125,016,723...125,026,228
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain 1 |
disease_progression |
ISO |
associated with lung adenocarcinoma; protein:increased expression:lung (human) |
RGD |
PMID:21966491 |
RGD:153344600 |
NCBI chr 6:90,636,578...90,965,766
Ensembl chr 6:90,633,070...90,965,667
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
|
ISO |
associated with non-small cell lung carcinoma, |
RGD |
PMID:28537888 |
RGD:13792830 |
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Kcnj12 |
potassium inwardly-rectifying channel, subfamily J, member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chr11:60,912,970...60,964,095
Ensembl chr11:60,913,390...60,961,957
|
|
G |
Kdr |
kinase insert domain protein receptor |
treatment |
IMP |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21383688 |
|
NCBI chr 1:133,249,625...133,257,460
Ensembl chr 1:133,237,565...133,257,460 Ensembl chr 1:133,237,565...133,257,460
|
|
G |
Klf7 |
Kruppel-like transcription factor 7 (ubiquitous) |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:37734194 |
|
NCBI chr 1:64,068,607...64,161,504
Ensembl chr 1:64,068,606...64,161,441
|
|
G |
Kmt2d |
lysine (K)-specific methyltransferase 2D |
|
ISO |
associated with stomach cancer |
RGD |
PMID:30177394 |
RGD:150521710 |
NCBI chr15:98,729,550...98,771,958
Ensembl chr15:98,729,550...98,769,085
|
|
G |
Lamc2 |
laminin, gamma 2 |
|
ISO |
associated with lung squamous cell carcinoma; |
RGD |
PMID:23124251 |
RGD:13793371 |
NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193
|
|
G |
Lrrc59 |
leucine rich repeat containing 59 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr11:94,520,603...94,536,049
Ensembl chr11:94,520,593...94,536,042
|
|
G |
Macir |
macrophage immunometabolism regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr 1:97,571,627...97,589,743
Ensembl chr 1:97,534,043...97,589,799
|
|
G |
Met |
met proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979
|
|
G |
Mir125a |
microRNA 125a |
|
ISO |
associated with stomach cancer; |
RGD |
PMID:22322911 |
RGD:21408544 |
NCBI chr17:18,051,074...18,051,141
Ensembl chr17:18,051,074...18,051,141
|
|
G |
Mir152 |
microRNA 152 |
|
ISO |
associated with breast cancer |
RGD |
PMID:22935141 |
RGD:19165152 |
NCBI chr11:96,741,219...96,741,291
Ensembl chr11:96,741,219...96,741,291
|
|
G |
Mir155 |
microRNA 155 |
disease_progression |
ISO |
associated with colon cancer |
RGD |
PMID:26885061 PMID:29893326 PMID:27856635 |
RGD:21079444, RGD:21409756, RGD:21079446 |
NCBI chr16:84,511,028...84,511,092
Ensembl chr16:84,511,028...84,511,092
|
|
G |
Mir187 |
microRNA 187 |
|
ISO |
associated with oral squamous cell carcinoma; RNA:increased expression:plasma |
RGD |
PMID:27542258 |
RGD:14390167 |
NCBI chr18:24,562,167...24,562,227
Ensembl chr18:24,562,167...24,562,227
|
|
G |
Mir224 |
microRNA 224 |
|
ISO |
associated with colorectal cancer; mRNA:decreased expression:colorectal mucosa: |
RGD |
PMID:25919696 |
RGD:14398749 |
NCBI chr X:71,304,637...71,304,718
Ensembl chr X:71,304,637...71,304,718
|
|
G |
Mir30a |
microRNA 30a |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:23486085 |
RGD:13432035 |
NCBI chr 1:23,311,350...23,311,420
Ensembl chr 1:23,311,350...23,311,420
|
|
G |
Mir335 |
microRNA 335 |
|
ISO |
associated with stomach cancer; RNA:decreased expression:stomach |
RGD |
PMID:21822301 |
RGD:14394425 |
NCBI chr 6:30,741,298...30,741,395
Ensembl chr 6:30,741,298...30,741,395
|
|
G |
Mir432 |
microRNA 432 |
disease_progression |
ISO |
mRNA:decreased expression:colon (human) |
RGD |
PMID:33717244 |
RGD:152999433 |
NCBI chr12:109,561,390...109,561,464
Ensembl chr12:109,561,390...109,561,464
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
disease_progression |
ISO |
associated with Tongue Neoplasms associated with Carcinoma, Ductal, Breast |
RGD |
PMID:23107277 PMID:23280016 |
RGD:8547824, RGD:8655998 |
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
|
ISO |
associated with breast cancer;DNA:deletion:promoter:-1170_-1172delA (human) |
RGD |
PMID:15161710 |
RGD:8662937 |
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
disease_progression |
ISO |
associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum associated with Tongue Neoplasms associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:20704821 PMID:23107277 PMID:12487935 |
RGD:5129215, RGD:8547824, RGD:2298523 |
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Msh2 |
mutS homolog 2 |
|
ISO |
associated with laryngeal squamous cell carcinoma |
RGD |
PMID:24459922 |
RGD:126848797 |
NCBI chr17:87,979,960...88,031,141
Ensembl chr17:87,979,758...88,031,141
|
|
G |
Msln |
mesothelin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22644300 |
|
NCBI chr17:25,967,587...25,973,352
Ensembl chr17:25,967,587...25,973,352
|
|
G |
Mta1 |
metastasis associated 1 |
|
ISO |
associated with Carcinoma, Non-Small-Cell Lung;mRNA:increased expression:lung |
RGD |
PMID:11804687 |
RGD:9588220 |
NCBI chr12:113,061,830...113,100,826
Ensembl chr12:113,061,898...113,100,826
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Muc1 |
mucin 1, transmembrane |
|
ISO |
associated with Common Bile Duct Neoplasms associated with Esophageal Neoplasms associated with Carcinoma, Renal Cell; associated with Gallbladder Neoplasms;protein:altered localization:gallbladder |
RGD |
PMID:16222735 PMID:21339746 PMID:10390012 PMID:11295067 |
RGD:2324649, RGD:7349383, RGD:7245968, RGD:2324860 |
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
|
|
G |
Muc5ac |
mucin 5, subtypes A and C, tracheobronchial/gastric |
|
ISO |
associated with chloangiocarcinoma;protein:increased expression:bile duct |
RGD |
PMID:16842244 |
RGD:2325168 |
NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
IMP |
|
RGD |
PMID:10086383 |
RGD:2326067 |
NCBI chr 9:49,413,434...49,710,909
Ensembl chr 9:49,413,436...49,710,225
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
ISO |
associated with Cervix Neoplasms; associated with Endometrial Neoplasms associated with Breast Neoplasms |
RGD |
PMID:8855975 PMID:8102131 PMID:9036878 |
RGD:2299062, RGD:2299077, RGD:2299061 |
NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
|
ISO |
associated with Cervix Neoplasms; associated with Endometrial Neoplasms |
RGD |
PMID:8855975 |
RGD:2299062 |
NCBI chr11:93,840,640...93,847,082
Ensembl chr11:93,840,640...93,847,085
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
susceptibility |
ISO |
associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human) |
RGD |
PMID:17262178 |
RGD:2292070 |
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human) |
RGD |
PMID:18977234 |
RGD:8657156 |
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
|
|
G |
Pagr1a |
PAXIP1 associated glutamate rich protein 1A |
disease_progression |
ISO |
protein:decreased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chr 7:126,614,223...126,616,524
Ensembl chr 7:126,614,205...126,616,524 Ensembl chr 7:126,614,205...126,616,524
|
|
G |
Pdgfa |
platelet derived growth factor, alpha |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:8619189 |
RGD:2292155 |
NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125
|
|
G |
Pdgfb |
platelet derived growth factor, B polypeptide |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17674348 |
RGD:2292173 |
NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase 1 |
|
ISO |
associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum |
RGD |
PMID:25064732 |
RGD:13503320 |
NCBI chr17:24,292,654...24,370,957
Ensembl chr17:24,292,654...24,369,898
|
|
G |
Pdpn |
podoplanin |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:18165897 PMID:16528371 |
RGD:2292231, RGD:2292237 |
NCBI chr 4:142,993,979...143,026,134
Ensembl chr 4:142,994,001...143,026,134
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:16243812 PMID:18191186 |
RGD:2302868, RGD:2302867 |
NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chr 9:98,920,455...99,022,264
Ensembl chr 9:98,918,707...99,022,674
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chr 3:94,965,841...95,014,241
Ensembl chr 3:94,965,841...95,014,241
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
|
ISO |
associated with Seminoma; associated with Carcinoma, Embryonal |
RGD |
PMID:15386301 |
RGD:2292442 |
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
|
ISO |
associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium |
RGD |
PMID:20021832 |
RGD:2317459 |
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:19305425 |
RGD:2314605 |
NCBI chr 2:166,408,265...166,555,752
Ensembl chr 2:166,408,262...166,555,752
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression:prostate associated with Breast Neoplasms |
RGD |
PMID:17163422 PMID:17919877 |
RGD:2292507, RGD:2292499 |
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
ISO |
associated with Biliary Tract Neoplasms associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human) associated with Breast Neoplasms |
RGD |
PMID:18159174 PMID:20016751 PMID:18353210 |
RGD:2317165, RGD:5135471, RGD:2300128 |
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
|
ISO |
associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
|
ISO |
associated with lung squamous cell carcinoma; protein:decreased expression:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chr 5:103,573,058...103,746,227
Ensembl chr 5:103,573,058...103,746,169
|
|
G |
Ramp2 |
receptor (calcitonin) activity modifying protein 2 |
disease_progression |
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chr11:101,137,160...101,139,076
Ensembl chr11:101,136,854...101,150,372
|
|
G |
Ramp3 |
receptor (calcitonin) activity modifying protein 3 |
|
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chr11:6,608,507...6,627,478
Ensembl chr11:6,608,521...6,627,475
|
|
G |
Rassf2 |
Ras association (RalGDS/AF-6) domain family member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17013896 |
|
NCBI chr 2:131,834,770...131,872,336
Ensembl chr 2:131,831,335...131,872,178
|
|
G |
Rbm10 |
RNA binding motif protein 10 |
|
ISO |
associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human) |
RGD |
PMID:30405763 |
RGD:151356993 |
NCBI chr X:20,483,596...20,517,128
Ensembl chr X:20,483,742...20,517,140
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
ISO |
associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland |
RGD |
PMID:17020979 |
RGD:2298757 |
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Ret |
ret proto-oncogene |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:18652760 |
RGD:2324925 |
NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
associated with Bladder Neoplasms;protein:increased expression:lymph node associated with colorectal cancer |
RGD |
PMID:12855641 PMID:17597401 |
RGD:2298872, RGD:13432052 |
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
|
ISO |
associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human) |
RGD |
PMID:20978191 |
RGD:152995469 |
NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882
|
|
G |
Runx1 |
runt related transcription factor 1 |
|
ISO |
associated with Carcinoid Tumor |
RGD |
PMID:21636701 |
RGD:126779567 |
NCBI chr16:92,398,354...92,622,962
Ensembl chr16:92,398,354...92,623,037
|
|
G |
Sfn |
stratifin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479
|
|
G |
Skp2 |
S-phase kinase-associated protein 2 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:16080017 |
RGD:2315043 |
NCBI chr15:9,112,070...9,155,512
Ensembl chr15:9,112,073...9,155,512
|
|
G |
Slc7a5 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 |
severity |
ISO |
associated with stomach carcinoma associated with gastric adenocarcinoma;protein:increased expression: : |
RGD |
PMID:25908107 PMID:21501294 |
RGD:11052781, RGD:151361203 |
NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433
|
|
G |
Smad4 |
SMAD family member 4 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:11809701 |
RGD:2300007 |
NCBI chr18:73,767,861...73,836,862
Ensembl chr18:73,772,080...73,836,851
|
|
G |
Smo |
smoothened, frizzled class receptor |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:30784110 |
RGD:150520177 |
NCBI chr 6:29,735,480...29,761,359
Ensembl chr 6:29,735,502...29,761,364
|
|
G |
Sncg |
synuclein, gamma |
|
ISO |
|
RGD |
PMID:15221989 |
RGD:6478801 |
NCBI chr14:34,092,231...34,096,626
Ensembl chr14:34,092,231...34,096,746
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:16707422 |
RGD:2298925 |
NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18097573 |
RGD:2298901 |
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
disease_progression |
ISO |
associated with tongue neoplasms; CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:10853026 PMID:19381893 PMID:20618948 PMID:20618948 |
RGD:8547519 |
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sox2 |
SRY (sex determining region Y)-box 2 |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:24382260 |
RGD:8661670 |
NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610
|
|
G |
Src |
Rous sarcoma oncogene |
|
ISO |
associated with colon adenocarcinoma, |
RGD |
PMID:21282564 |
RGD:150520218 |
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
St14 |
suppression of tumorigenicity 14 (colon carcinoma) |
|
ISO |
associated with Endometrial Neoplasms |
RGD |
PMID:19443387 |
RGD:2315087 |
NCBI chr 9:30,999,886...31,043,138
Ensembl chr 9:31,000,698...31,043,149
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21549414 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stk11 |
serine/threonine kinase 11 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:12114407 |
RGD:2291948 |
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Tert |
telomerase reverse transcriptase |
disease_progression |
ISO |
associated with lung non-small cell carcinoma; |
RGD |
PMID:11679180 |
RGD:152977755 |
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:12487935 |
RGD:2298523 |
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp3 |
tissue inhibitor of metalloproteinase 3 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370
|
|
G |
Timp4 |
tissue inhibitor of metalloproteinase 4 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chr 6:115,221,405...115,229,166
Ensembl chr 6:115,218,853...115,229,166
|
|
G |
Tlr4 |
toll-like receptor 4 |
|
ISO |
associated with Carcinoma, Ductal, Breast; |
RGD |
PMID:23338716 |
RGD:7794684 |
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Trmt11 |
tRNA methyltransferase 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr10:30,410,218...30,477,598
Ensembl chr10:30,410,221...30,476,745
|
|
G |
Trp53 |
transformation related protein 53 |
|
ISO IMP |
associated with Penile Neoplasms associated with Carcinoma, Squamous Cell; associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P |
RGD |
PMID:18268397 PMID:18059331 PMID:18230179 |
RGD:2290533, RGD:8547790, RGD:2290534 |
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp53bp1 |
transformation related protein 53 binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr 2:121,025,316...121,126,830
Ensembl chr 2:121,023,762...121,101,888
|
|
G |
Tsc2 |
TSC complex subunit 2 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:15951164 |
RGD:11568707 |
NCBI chr17:24,814,788...24,851,607
Ensembl chr17:24,814,790...24,851,604
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9062474 |
|
NCBI chr12:91,367,767...91,507,283
Ensembl chr12:91,351,337...91,516,582
|
|
G |
Ttr |
transthyretin |
|
ISO |
associated with colorectal cancer;protein:decreased expresion:blood serum (human) |
RGD |
PMID:21074777 |
RGD:151665155 |
NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378
|
|
G |
Tymp |
thymidine phosphorylase |
|
ISO |
associated with Cholangiocarcinoma associated with Breast Neoplasms |
RGD |
PMID:11927969 PMID:10685502 |
RGD:2325027, RGD:2293725 |
NCBI chr15:89,255,834...89,261,282
Ensembl chr15:89,256,134...89,261,242
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO IMP |
associated with Cervix Neoplasms associated with Breast neoplasms; |
RGD |
PMID:19783962 PMID:17597103 |
RGD:2315454, RGD:7421574 |
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfc |
vascular endothelial growth factor C |
exacerbates disease_progression |
ISO |
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human) associated with Lymphatic Metastasis; associated with thyroid diseases;mRNA:increased expression:thyroid gland: associated with Breast Neoplasms associated with Prostatic Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:17034609 PMID:18061373 PMID:15289890 PMID:12203051 PMID:19923084 PMID:19608016 PMID:19589137 More...
|
RGD:2315484, RGD:155630642, RGD:7488946, RGD:7483611, RGD:2315469, RGD:2315474, RGD:2315475 |
NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131
|
|
G |
Vegfd |
vascular endothelial growth factor D |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:19589137 PMID:17951197 |
RGD:2315475, RGD:2315480 |
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Wrap53 |
WD repeat containing, antisense to Trp53 |
|
ISO |
associated with lung non-small cell carcinoma; associated with esophagus squamous cell carcinoma; |
RGD |
PMID:31281482 PMID:24626331 |
RGD:21081513, RGD:21081532 |
NCBI chr11:69,452,580...69,471,076
Ensembl chr11:69,452,584...69,471,081
|
|
|
G |
Aco1 |
aconitase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338
|
|
G |
Actb |
actin, beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23289900 |
|
NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001
|
|
G |
Ahnak |
AHNAK nucleoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25826687 PMID:27752740 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akr1b10 |
aldo-keto reductase family 1, member B10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25686905 |
|
NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885
|
|
G |
Alkbh8 |
alkB homolog 8, tRNA methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 9:3,335,151...3,391,154
Ensembl chr 9:3,335,140...3,391,154
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Ambp |
alpha 1 microglobulin/bikunin precursor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:14644129 |
|
NCBI chr 4:63,061,512...63,072,409
Ensembl chr 4:63,061,512...63,073,036
|
|
G |
Amotl1 |
angiomotin-like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34480788 |
|
NCBI chr 9:14,453,262...14,574,408
Ensembl chr 9:14,453,262...14,556,352
|
|
G |
Angpt1 |
angiopoietin 1 |
|
ISO |
associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland |
RGD |
PMID:15459484 |
RGD:1626167 |
NCBI chr15:42,288,063...42,540,373
Ensembl chr15:42,288,119...42,540,373
|
|
G |
Angptl4 |
angiopoietin-like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Anxa2 |
annexin A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27517156 |
|
NCBI chr11:59,102,237...59,119,042
Ensembl chr11:59,102,238...59,119,096
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
Bcar1 |
breast cancer anti-estrogen resistance 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chr 8:112,437,106...112,470,481
Ensembl chr 8:112,437,106...112,470,441
|
|
G |
Brms1 |
breast cancer metastasis-suppressor 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chr19:5,091,391...5,099,940
Ensembl chr19:5,091,382...5,099,945
|
|
G |
Bsg |
basigin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21165561 |
|
NCBI chr10:79,540,192...79,547,813
Ensembl chr10:79,540,325...79,547,803
|
|
G |
Calr |
calreticulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Calu |
calumenin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 6:29,348,105...29,376,674
Ensembl chr 6:29,348,068...29,377,109
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21749277 PMID:22580338 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25199511 PMID:32512068 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:36346222 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18985009 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cd82 |
CD82 antigen |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20075392 |
|
NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:19839049 PMID:22580338 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24495407 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cfl1 |
cofilin 1, non-muscle |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21029458 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Chrna7 |
cholinergic receptor, nicotinic, alpha polypeptide 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 |
|
NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317
|
|
G |
Cse1l |
chromosome segregation 1 like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34022224 |
|
NCBI chr 2:166,747,961...166,788,309
Ensembl chr 2:166,747,960...166,788,309
|
|
G |
Cstb |
cystatin B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19747051 PMID:22287159 |
|
NCBI chr10:78,261,504...78,263,456
Ensembl chr10:78,261,503...78,263,456
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28414304 |
|
NCBI chr 7:132,588,727...132,726,048
Ensembl chr 7:132,589,292...132,726,083
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23707762 PMID:26990689 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsb |
cathepsin B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 PMID:19747051 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Ctss |
cathepsin S |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 7:43,321,400...43,327,724
Ensembl chr 7:43,321,440...43,327,722
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 8:123,202,882...123,209,831
Ensembl chr 8:123,202,882...123,210,877
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 PMID:25231984 PMID:25753200 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32512068 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25753200 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 PMID:27811057 |
|
NCBI chr13:47,238,243...47,261,134
Ensembl chr13:47,238,251...47,259,677
|
|
G |
Dlx4 |
distal-less homeobox 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr11:95,031,273...95,037,116
Ensembl chr11:95,031,273...95,037,089
|
|
G |
Dmd |
dystrophin, muscular dystrophy |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chr X:81,858,244...84,248,656
Ensembl chr X:81,992,476...84,249,747
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28544374 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Ednrb |
endothelin receptor type B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21554491 |
|
NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332
|
|
G |
Egf |
epidermal growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15802018 PMID:22869556 PMID:23064031 PMID:24587105 PMID:27634460 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:23867902 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457
|
|
G |
Elp1 |
elongator complex protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 4:56,746,547...56,802,565
Ensembl chr 4:56,749,680...56,802,331
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr14:65,767,895...65,830,561
Ensembl chr14:65,767,898...65,830,524
|
|
G |
En1 |
engrailed 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 1:120,530,246...120,535,719
Ensembl chr 1:120,530,147...120,535,721
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 PMID:30090327 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Epo |
erythropoietin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19799886 |
|
NCBI chr 6:137,454,242...137,626,262
Ensembl chr 6:137,454,243...137,631,874
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:26990689 PMID:27366082 PMID:35044086 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Fam83a |
family with sequence similarity 83, member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34931434 |
|
NCBI chr15:57,847,983...57,874,102
Ensembl chr15:57,848,815...57,874,405
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
ISO |
ClinVar Annotator: match by term: Cancer progression and tumor cell motility |
ClinVar |
PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287 |
|
NCBI chr13:55,300,631...55,316,572
Ensembl chr13:55,300,453...55,316,572
|
|
G |
Fn1 |
fibronectin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chr 6:98,902,303...99,510,587
Ensembl chr 6:98,902,299...99,499,682
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Gab2 |
growth factor receptor bound protein 2-associated protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chr 7:96,730,958...96,958,158
Ensembl chr 7:96,730,793...96,958,153
|
|
G |
Glycam1 |
glycosylation dependent cell adhesion molecule 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr15:103,471,186...103,473,508
Ensembl chr15:103,471,186...103,473,508
|
|
G |
Grep1 |
glycine rich extracellular protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34652879 |
|
NCBI chr17:23,923,582...23,945,299
Ensembl chr17:23,923,462...23,941,757
|
|
G |
H19 |
H19, imprinted maternally expressed transcript |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28544374 |
|
NCBI chr 7:142,129,267...142,131,883
Ensembl chr 7:142,129,262...142,131,917
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34973135 |
|
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9932610 PMID:15654357 |
|
NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12811834 PMID:29501572 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28830677 |
|
NCBI chr10:120,197,173...120,312,374
Ensembl chr10:120,197,180...120,312,374
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27816970 |
|
NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24211270 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxb13 |
homeobox B13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr11:96,085,142...96,087,436
Ensembl chr11:96,085,142...96,088,273
|
|
G |
Hoxb3 |
homeobox B3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34652879 |
|
NCBI chr11:96,197,927...96,238,756
Ensembl chr11:96,214,152...96,238,756
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23877152 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Id4 |
inhibitor of DNA binding 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14633621 |
|
NCBI chr13:48,414,592...48,419,504
Ensembl chr13:48,414,704...48,419,502
|
|
G |
Igf1 |
insulin-like growth factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il1b |
interleukin 1 beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27567548 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27567548 |
|
NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506
|
|
G |
Il6 |
interleukin 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 PMID:26284488 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins2 |
insulin II |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24587105 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chr 9:54,769,942...54,819,812
Ensembl chr 9:54,771,073...54,819,814
|
|
G |
Itga5 |
integrin alpha 5 (fibronectin receptor alpha) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itpk1 |
inositol 1,3,4-triphosphate 5/6 kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr12:102,534,842...102,671,128
Ensembl chr12:102,534,841...102,671,189
|
|
G |
Kcnd2 |
potassium voltage-gated channel, Shal-related family, member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34418280 |
|
NCBI chr 6:21,212,101...21,729,804
Ensembl chr 6:21,215,502...21,729,804
|
|
G |
Kdm1a |
lysine (K)-specific demethylase 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22493729 |
|
NCBI chr 4:136,277,844...136,330,127
Ensembl chr 4:136,277,851...136,330,034
|
|
G |
Krt19 |
keratin 19 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr11:100,031,636...100,036,752
Ensembl chr11:100,031,636...100,039,491
|
|
G |
Krt7 |
keratin 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19921857 |
|
NCBI chr15:101,310,284...101,325,687
Ensembl chr15:101,308,924...101,328,194
|
|
G |
Ldhb |
lactate dehydrogenase B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 6:142,435,975...142,453,683
Ensembl chr 6:142,435,975...142,453,683
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lin28a |
lin-28 homolog A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26910839 |
|
NCBI chr 4:133,730,641...133,746,504
Ensembl chr 4:133,730,641...133,746,152
|
|
G |
Loxl2 |
lysyl oxidase-like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chr14:69,846,085...69,933,283
Ensembl chr14:69,846,517...69,933,283
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25538231 PMID:26735578 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,852,706
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Met |
met proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979
|
|
G |
Mir141 |
microRNA 141 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27616325 |
|
NCBI chr 6:124,694,877...124,694,948
Ensembl chr 6:124,694,877...124,694,948
|
|
G |
Mir155 |
microRNA 155 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28315615 |
|
NCBI chr16:84,511,028...84,511,092
Ensembl chr16:84,511,028...84,511,092
|
|
G |
Mir186 |
microRNA 186 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chr 3:157,249,916...157,249,986
Ensembl chr 3:157,249,916...157,249,986
|
|
G |
Mir191 |
microRNA 191 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29277653 |
|
NCBI chr 9:108,445,518...108,445,591
Ensembl chr 9:108,445,518...108,445,591
|
|
G |
Mir200b |
microRNA 200b |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:19839049 |
|
NCBI chr 4:156,140,138...156,140,207
Ensembl chr 4:156,140,138...156,140,207
|
|
G |
Mir200c |
microRNA 200c |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:19839049 |
|
NCBI chr 6:124,695,285...124,695,353
Ensembl chr 6:124,695,285...124,695,353
|
|
G |
Mir215 |
microRNA 215 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:28887306 |
|
NCBI chr 1:185,045,778...185,045,889
Ensembl chr 1:185,045,778...185,045,889
|
|
G |
Mir217 |
microRNA 217 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25538231 |
|
NCBI chr11:28,713,728...28,713,835
Ensembl chr11:28,713,728...28,713,835
|
|
G |
Mir21a |
microRNA 21a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 PMID:29501572 |
|
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir346 |
microRNA 346 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27501413 PMID:27777383 |
|
NCBI chr14:34,616,566...34,616,663
Ensembl chr14:34,616,566...34,616,663
|
|
G |
Mir497 |
microRNA 497 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35066776 |
|
NCBI chr11:70,125,543...70,125,626
Ensembl chr11:70,125,543...70,125,626
|
|
G |
Mir532 |
microRNA 532 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30639441 |
|
NCBI chr X:7,114,641...7,114,736
Ensembl chr X:7,114,641...7,114,736
|
|
G |
Mir543 |
microRNA 543 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:30710498 |
|
NCBI chr12:109,683,692...109,683,767
Ensembl chr12:109,683,692...109,683,767
|
|
G |
Mir708 |
microRNA 708 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:34652879 |
|
NCBI chr 7:95,898,631...95,898,739
Ensembl chr 7:95,898,631...95,898,739
|
|
G |
Mir874 |
microRNA 874 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:30004169 |
|
NCBI chr13:58,170,939...58,171,014
Ensembl chr13:58,170,939...58,171,014
|
|
G |
Mmp14 |
matrix metallopeptidase 14 (membrane-inserted) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20188714 PMID:26284488 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 PMID:23867902 PMID:24333868 More...
|
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mt2 |
metallothionein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21187089 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mt3 |
metallothionein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23794209 |
|
NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774
|
|
G |
Mtdh |
metadherin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29315995 |
|
NCBI chr15:34,082,613...34,143,683
Ensembl chr15:34,082,840...34,145,770
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Myh9 |
myosin, heavy polypeptide 9, non-muscle |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chr15:77,644,788...77,726,315
Ensembl chr15:77,644,787...77,726,375
|
|
G |
Mylk |
myosin, light polypeptide kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10232591 PMID:12970723 |
|
NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chr 9:49,413,434...49,710,909
Ensembl chr 9:49,413,436...49,710,225
|
|
G |
Nek2 |
NIMA (never in mitosis gene a)-related expressed kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28509438 |
|
NCBI chr 1:191,553,622...191,565,161
Ensembl chr 1:191,553,556...191,565,162
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347
|
|
G |
Notch2 |
notch 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30670679 |
|
NCBI chr 3:97,920,854...98,057,683
Ensembl chr 3:97,920,843...98,057,677
|
|
G |
Nrg1 |
neuregulin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Nuak1 |
NUAK family, SNF1-like kinase, 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 PMID:26873845 |
|
NCBI chr10:84,206,764...84,282,028
Ensembl chr10:84,206,769...84,276,461
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35066776 |
|
NCBI chr 7:97,437,748...97,561,588
Ensembl chr 7:97,437,748...97,561,588
|
|
G |
Pax6 |
paired box 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709
|
|
G |
Pdcd4 |
programmed cell death 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23272133 |
|
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chr 3:94,965,841...95,014,241
Ensembl chr 3:94,965,841...95,014,241
|
|
G |
Pkm |
pyruvate kinase, muscle |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 PMID:15654357 |
|
NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658
|
|
G |
Plau |
plasminogen activator, urokinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14644129 PMID:26284488 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22261521 |
|
NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393
|
|
G |
Ppp1r12b |
protein phosphatase 1, regulatory subunit 12B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chr 1:134,682,396...134,883,699
Ensembl chr 1:134,682,396...134,883,680
|
|
G |
Prdx2 |
peroxiredoxin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23911960 |
|
NCBI chr 8:85,696,251...85,701,440
Ensembl chr 8:85,696,216...85,701,463
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21994956 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:12811834 PMID:25199511 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Pvt1 |
Pvt1 oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35213076 |
|
NCBI chr15:61,909,835...62,132,064
Ensembl chr15:61,909,817...62,249,945
|
|
G |
Rab27a |
RAB27A, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chr 9:72,952,092...73,004,905
Ensembl chr 9:72,952,136...73,004,911
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chr18:70,112,202...70,274,704
Ensembl chr18:70,112,202...70,274,676
|
|
G |
Rasal2 |
RAS protein activator like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34826200 |
|
NCBI chr 1:156,962,759...157,240,170
Ensembl chr 1:156,962,752...157,240,165
|
|
G |
Rbm38 |
RNA binding motif protein 38 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:34453780 |
|
NCBI chr 2:172,863,722...172,876,527
Ensembl chr 2:172,862,291...172,876,527
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20127710 |
|
NCBI chr 4:43,875,521...43,944,806
Ensembl chr 4:43,875,530...43,944,806
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 PMID:29501572 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rnf207 |
ring finger protein 207 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 4:152,391,475...152,403,686
Ensembl chr 4:152,391,476...152,403,450
|
|
G |
Rpl3l |
ribosomal protein L3-like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr17:24,946,800...24,955,117
Ensembl chr17:24,946,794...24,955,117
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase polypeptide 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21488662 |
|
NCBI chr X:158,038,652...158,151,240
Ensembl chr X:157,993,303...158,151,240
|
|
G |
Rpsa |
ribosomal protein SA |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 9:119,956,832...119,961,435
Ensembl chr 9:119,956,755...119,961,435
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chr 3:93,427,803...93,433,595
Ensembl chr 3:93,427,795...93,433,594
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 3:90,511,077...90,513,349
Ensembl chr 3:90,511,078...90,513,352
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26518876 |
|
NCBI chr 9:20,877,248...20,888,089
Ensembl chr 9:20,873,657...20,888,077
|
|
G |
Septin9 |
septin 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chr11:117,090,487...117,253,151
Ensembl chr11:117,090,487...117,253,151
|
|
G |
Set |
SET nuclear oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24555657 |
|
NCBI chr 2:29,952,074...29,962,589
Ensembl chr 2:29,947,390...29,962,589
|
|
G |
Slc39a10 |
solute carrier family 39 (zinc transporter), member 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17359283 |
|
NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012
|
|
G |
Slc6a12 |
solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 6:121,319,533...121,342,732
Ensembl chr 6:121,320,035...121,342,734
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1, acid lysosomal |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24951586 |
|
NCBI chr 7:105,203,567...105,207,596
Ensembl chr 7:105,203,567...105,207,596
|
|
G |
Snai1 |
snail family zinc finger 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 PMID:24014025 |
|
NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734
|
|
G |
Snai2 |
snail family zinc finger 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chr16:14,523,716...14,527,259
Ensembl chr16:14,523,716...14,527,249
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 PMID:22580338 More...
|
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sorl1 |
sortilin-related receptor, LDLR class A repeats-containing |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 9:41,876,005...42,035,593
Ensembl chr 9:41,876,016...42,035,593
|
|
G |
Sox11 |
SRY (sex determining region Y)-box 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr12:27,384,267...27,392,717
Ensembl chr12:27,384,263...27,392,573
|
|
G |
Sox9 |
SRY (sex determining region Y)-box 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26317792 PMID:35072892 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Src |
Rous sarcoma oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:21291860 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993
|
|
G |
Tbx15 |
T-box 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 3:99,147,671...99,261,576
Ensembl chr 3:99,147,697...99,261,575
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
|
ISO |
|
RGD |
PMID:11687973 |
RGD:11060269 |
NCBI chr 6:3,962,589...3,988,977
Ensembl chr 6:3,962,595...3,988,919
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 PMID:32745479 More...
|
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgif1 |
TGFB-induced factor homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25791921 |
|
NCBI chr17:71,151,200...71,160,527
Ensembl chr17:71,151,200...71,160,541
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:1318976 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp3 |
tissue inhibitor of metalloproteinase 3 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:23109338 |
|
NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370
|
|
G |
Tkt |
transketolase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677
|
|
G |
Tln1 |
talin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chr 4:43,531,513...43,562,583
Ensembl chr 4:43,531,519...43,562,691
|
|
G |
Tlr4 |
toll-like receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tmem139 |
transmembrane protein 139 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 6:42,238,866...42,241,489
Ensembl chr 6:42,238,893...42,241,489
|
|
G |
Tnf |
tumor necrosis factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trf |
transferrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643
|
|
G |
Trim47 |
tripartite motif-containing 47 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:31981573 |
|
NCBI chr11:115,996,576...116,001,061
Ensembl chr11:115,996,578...116,018,036
|
|
G |
Trp53bp2 |
transformation related protein 53 binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chr 1:182,236,737...182,289,997
Ensembl chr 1:182,236,737...182,289,997
|
|
G |
Trpm7 |
transient receptor potential cation channel, subfamily M, member 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30710498 |
|
NCBI chr 2:126,633,478...126,718,181
Ensembl chr 2:126,633,485...126,718,150
|
|
G |
Twist1 |
twist basic helix-loop-helix transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22155737 |
|
NCBI chr12:34,007,670...34,009,830
Ensembl chr12:34,007,670...34,009,828
|
|
G |
Txn1 |
thioredoxin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Ubqln1 |
ubiquilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24747970 |
|
NCBI chr13:58,323,970...58,363,467
Ensembl chr13:58,323,970...58,363,467
|
|
G |
Vim |
vimentin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Xpc |
xeroderma pigmentosum, complementation group C |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27777383 |
|
NCBI chr 6:91,466,287...91,492,870
Ensembl chr 6:91,466,287...91,492,870
|
|
G |
Xrcc3 |
X-ray repair complementing defective repair in Chinese hamster cells 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21283680 |
|
NCBI chr12:111,769,626...111,780,326
Ensembl chr12:111,769,626...111,780,307
|
|
G |
Yap1 |
yes-associated protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chr 9:48,563,097...48,747,525
Ensembl chr 9:48,565,597...48,747,522
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chr18:5,591,330...5,775,468
Ensembl chr18:5,591,860...5,775,467
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chr 2:44,873,523...45,007,378
Ensembl chr 2:44,873,644...45,007,407
|
|
G |
Zfas1 |
zinc finger, NFX1-type containing 1, antisense RNA 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35072892 |
|
NCBI chr 2:166,904,854...166,907,782
Ensembl chr 2:166,904,854...166,907,783
|
|
G |
Zfp36 |
zinc finger protein 36 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25556371 |
|
NCBI chr 7:28,076,208...28,078,680
Ensembl chr 7:28,076,209...28,079,678
|
|
G |
Zfp367 |
zinc finger protein 367 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chr13:64,280,836...64,301,013
Ensembl chr13:64,280,832...64,301,016
|
|
G |
Zfr |
zinc finger RNA binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34323000 |
|
NCBI chr15:12,117,649...12,185,535
Ensembl chr15:12,117,917...12,185,769
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12015757 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17003774 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Ace |
angiotensin I converting enzyme |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chr 1:90,131,702...90,143,446
Ensembl chr 1:90,131,702...90,144,473
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
|
ISO |
associated with pheochromocytoma |
RGD |
PMID:29067245 |
RGD:13831131 |
NCBI chr 9:54,512,163...54,569,169
Ensembl chr 9:54,512,161...54,569,154
|
|
G |
Acvr2a |
activin receptor IIA |
exacerbates |
ISO |
associated with colon cancer;mRNA,protein:decreased expression:colon (human) |
RGD |
PMID:30310521 |
RGD:151361136 |
NCBI chr 2:48,704,121...48,793,276
Ensembl chr 2:48,704,121...48,793,281
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:9772287 |
RGD:13831353 |
NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314
|
|
G |
Adora2b |
adenosine A2b receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27590504 |
|
NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21948867 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akirin2 |
akirin 2 |
|
ISO |
|
RGD |
PMID:18460465 |
RGD:2306009 |
NCBI chr 4:34,550,615...34,566,930
Ensembl chr 4:34,550,937...34,566,908
|
|
G |
Akt2 |
thymoma viral proto-oncogene 2 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:19491266 |
RGD:2315599 |
NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251
|
|
G |
Alk |
anaplastic lymphoma kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chr17:72,174,206...72,911,719
Ensembl chr17:72,175,967...72,911,622
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
|
IMP |
Liver Metastasis |
RGD |
PMID:28272394 |
RGD:14394499 |
NCBI chr15:97,141,955...97,145,168
Ensembl chr15:97,142,006...97,145,168
|
|
G |
Angptl4 |
angiopoietin-like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804
|
|
G |
Antxr1 |
anthrax toxin receptor 1 |
|
ISO |
associated with Mammary Neoplasms, Experimental; |
RGD |
PMID:22085271 |
RGD:9684855 |
NCBI chr 6:87,110,835...87,312,757
Ensembl chr 6:87,110,835...87,312,803
|
|
G |
Anxa1 |
annexin A1 |
treatment |
ISO IMP |
associated with Mammary Neoplasms, Experimental;protein:increased expression:lung CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20308542 PMID:9514092 PMID:20308542 PMID:20821804 PMID:20821804 |
RGD:2306939, RGD:7421563, RGD:7421541, RGD:7421541 |
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Anxa4 |
annexin A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566
|
|
G |
Anxa7 |
annexin A7 |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression:prostate gland associated with Breast Neoplasms;protein:increased expression:breast |
RGD |
PMID:11287641 PMID:15073110 |
RGD:2292656, RGD:2292655 |
NCBI chr14:20,505,344...20,530,009
Ensembl chr14:20,505,328...20,530,201
|
|
G |
Apoe |
apolipoprotein E |
|
IMP |
|
RGD |
PMID:22469977 |
RGD:7771597 |
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450
|
|
G |
Arid1a |
AT-rich interaction domain 1A |
disease_progression |
IMP |
in lung; associated with hepatocellular carcinoma |
RGD |
PMID:25975202 |
RGD:125097495 |
NCBI chr 4:133,406,319...133,484,682
Ensembl chr 4:133,406,319...133,484,080
|
|
G |
Atp6v1c1 |
ATPase, H+ transporting, lysosomal V1 subunit C1 |
|
IMP |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:24155661 |
RGD:14700647 |
NCBI chr15:38,662,096...38,692,688
Ensembl chr15:38,662,177...38,692,690
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
Azin1 |
antizyme inhibitor 1 |
|
ISO |
associated with stomach cancer;RNA:increased editing:stomach associated with colorectal cancer;RNA:increased editing:colorectum |
RGD |
PMID:30563560 PMID:29925690 |
RGD:14700703, RGD:14700704 |
NCBI chr15:38,487,674...38,523,506
Ensembl chr15:38,487,671...38,519,510
|
|
G |
Bax |
BCL2-associated X protein |
|
ISO |
associated with Carcinoma, Infiltrating Duct |
RGD |
PMID:17288732 |
RGD:1643356 |
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
|
ISO |
associated with Breast Neoplasms associated with Carcinoma, Renal Cell |
RGD |
PMID:16826579 PMID:12810203 |
RGD:2293020, RGD:2293021 |
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
severity |
ISO |
associated with Prostatic Neoplasms;protein:increased expression:bone |
RGD |
PMID:16166304 |
RGD:2289018 |
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
disease_progression |
ISO |
associated with Breast Neoplasms;protein:increased expression:breast associated with Prostatic Neoplasms;mRNA:increased expression:bone |
RGD |
PMID:17895257 PMID:12539225 |
RGD:2289029, RGD:2289033 |
NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114
|
|
G |
Braf |
Braf transforming gene |
onset |
ISO |
associated with Melanoma; DNA:mutations: : |
RGD |
PMID:25623140 |
RGD:11567259 |
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
|
|
G |
Brd4 |
bromodomain containing 4 |
|
ISO |
|
RGD |
PMID:23950209 |
RGD:9586346 |
NCBI chr17:32,415,246...32,503,717
Ensembl chr17:32,415,248...32,503,696
|
|
G |
Brms1 |
breast cancer metastasis-suppressor 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chr19:5,091,391...5,099,940
Ensembl chr19:5,091,382...5,099,945
|
|
G |
Bsg |
basigin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21956400 |
|
NCBI chr10:79,540,192...79,547,813
Ensembl chr10:79,540,325...79,547,803
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:28605041 |
RGD:14398832 |
NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297
|
|
G |
Cacybp |
calcyclin binding protein |
|
ISO |
associated with pancreatic neoplasms |
RGD |
PMID:18765951 |
RGD:2326146 |
NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445
|
|
G |
Calml3 |
calmodulin-like 3 |
ameliorates |
ISO |
associated with hepatocellular carcinoma; human cells in mouse model associated with hepatocellular carcinoma; protein:decreased expression:liver (human) |
RGD |
PMID:29445139 PMID:29445139 |
RGD:151665319, RGD:151665319 |
NCBI chr13:3,852,893...3,854,318
Ensembl chr13:3,852,896...3,854,316
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
|
ISO |
associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas |
RGD |
PMID:19188911 |
RGD:2326238 |
NCBI chr 4:122,752,841...122,779,869
Ensembl chr 4:122,752,840...122,779,849
|
|
G |
Casp3 |
caspase 3 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18064531 |
RGD:2293306 |
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:12538496 PMID:22580338 PMID:23518002 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
treatment |
IMP ISO |
associated with Mammary Neoplasms, Experimental CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20562527 PMID:15355971 PMID:15334058 |
RGD:2289106, RGD:8661780 |
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cbx4 |
chromobox 4 |
|
ISO |
associated with Carcinoma, Hepatocellular; |
RGD |
PMID:24838576 |
RGD:9586738 |
NCBI chr11:118,968,399...118,977,067
Ensembl chr11:118,968,399...118,977,047
|
|
G |
Cbx5 |
chromobox 5 |
|
ISO |
associated with Lung Neoplasms; |
RGD |
PMID:22900142 |
RGD:9586743 |
NCBI chr15:103,099,973...103,148,337
Ensembl chr15:103,099,971...103,148,243
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
|
IMP |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:19629725 |
RGD:4891450 |
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30603057 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
|
IMP |
|
RGD |
PMID:18941229 |
RGD:7241810 |
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
IMP |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccn4 |
cellular communication network factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30723155 |
|
NCBI chr15:66,763,337...66,795,050
Ensembl chr15:66,763,169...66,795,050
|
|
G |
Ccna2 |
cyclin A2 |
|
ISO |
associated with Seminoma;protein:increased expression:testis |
RGD |
PMID:14696091 |
RGD:2293346 |
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnd1 |
cyclin D1 |
treatment |
ISO |
associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant associated with stomach cancer; human cells in mouse model |
RGD |
PMID:18715616 PMID:27431311 |
RGD:13434926, RGD:152995400 |
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with Breast Neoplasms;DNA:hypermethylated:brain |
RGD |
PMID:15131050 |
RGD:2289155 |
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccne1 |
cyclin E1 |
disease_progression |
IDA ISO |
protein:altered processing associated with non-small cell lung carcinoma |
RGD |
PMID:17671189 PMID:11212263 |
RGD:2289229, RGD:13673913 |
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35072892 |
|
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Cd274 |
CD274 antigen |
disease_progression |
ISO |
associated with ovarian cancer |
RGD |
PMID:23340297 |
RGD:41410797 |
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd44 |
CD44 antigen |
|
ISO |
associated with Carcinoma, Renal Cell;protein:increased expression:kidney CTD Direct Evidence: marker/mechanism associated with Breast Neoplasm;protein:increased expression:liver |
CTD RGD |
PMID:23098472 PMID:18026989 PMID:17991717 |
RGD:2289347, RGD:2289349 |
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd82 |
CD82 antigen |
|
ISO |
associated with Prostatic Neoplasms;DNA:loss of heterozygosity CTD Direct Evidence: therapeutic associated with Carcinoma, Hepatocellular;mRNA:decreased expression associated with Prostatic Neoplasms;mRNA:decreased expression:bone associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain |
CTD RGD |
PMID:20075392 PMID:9254900 PMID:11275982 PMID:12806379 PMID:15592684 PMID:9831222 More...
|
RGD:2289425, RGD:2289407, RGD:2289402, RGD:2289400, RGD:68869 |
NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485
|
|
G |
Cd86 |
CD86 antigen |
|
ISO |
mRNA:decreased expression:mediastinal lymph node (rat) |
RGD |
PMID:18360875 |
RGD:4892237 |
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdh1 |
cadherin 1 |
treatment |
ISO |
associated with Prostatic Neoplasms associated with stomach cancer; human cells in mouse model CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:17520682 PMID:22580338 PMID:18008331 PMID:27431311 |
RGD:2289488, RGD:152995400 |
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23876460 |
|
NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303
|
|
G |
Cdkl2 |
cyclin dependent kinase like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25333262 |
|
NCBI chr 5:92,153,933...92,198,479
Ensembl chr 5:92,153,933...92,191,742
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Melanoma; |
RGD |
PMID:9194578 |
RGD:8662817 |
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
|
ISO |
associated with Paraganglioma, Extra-Adrenal;DNA:hypermethylation |
RGD |
PMID:18509008 |
RGD:8552280 |
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cfl1 |
cofilin 1, non-muscle |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229
|
|
G |
Cga |
glycoprotein hormones, alpha subunit |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:6768680 |
RGD:2293637 |
NCBI chr 4:34,893,779...34,907,374
Ensembl chr 4:34,893,779...34,907,370
|
|
G |
Chek1 |
checkpoint kinase 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15448002 |
RGD:2317235 |
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
IMP |
associated with prostate adenocarcinoma |
RGD |
PMID:17377533 |
RGD:2298657 |
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Cic |
capicua transcriptional repressor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chr 7:24,967,054...24,993,584
Ensembl chr 7:24,967,129...24,993,584
|
|
G |
Cldn7 |
claudin 7 |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chr11:69,855,605...69,858,712
Ensembl chr11:69,855,605...69,858,711
|
|
G |
Clic1 |
chloride intracellular channel 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725
|
|
G |
Clu |
clusterin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:20307318 |
RGD:8883512 |
NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29179997 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:18510570 |
RGD:2293638 |
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
exacerbates |
ISO IMP |
associated with Prostatic Neoplasms associated with breast cancer CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:1390197 PMID:18510570 PMID:25005824 |
RGD:2293638, RGD:150524287 |
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:7543699 PMID:9018096 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Cst3 |
cystatin C |
|
ISO |
protein:decreased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Csta2 |
cystatin A family member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20461718 |
|
NCBI chr16:36,041,932...36,077,813
Ensembl chr16:36,041,838...36,077,810
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
disease_progression |
IMP ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:15701862 PMID:18049334 |
RGD:4891518, RGD:7204722 |
NCBI chr 1:60,948,184...60,954,991
Ensembl chr 1:60,926,159...60,954,991
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
associated with Prostatic Neoplasms CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:29106415 PMID:18008331 |
RGD:2289488 |
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsb |
cathepsin B |
|
ISO |
protein:increased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
protein:increased expression:oral cavity, oropharynx, hypopharynx (human) |
RGD |
PMID:10562684 |
RGD:1547892 |
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Ctsh |
cathepsin H |
|
ISO |
protein:increased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chr 9:89,936,320...89,958,148
Ensembl chr 9:89,936,205...89,958,142
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 7:43,321,400...43,327,724
Ensembl chr 7:43,321,440...43,327,722
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr 8:123,202,882...123,209,831
Ensembl chr 8:123,202,882...123,210,877
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
susceptibility |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16627550 |
RGD:4892015 |
NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
treatment |
ISO |
associated with Pancreatic Neoplasms CTD Direct Evidence: marker/mechanism associated with Pancreatic Carcinoma |
CTD RGD |
PMID:21312072 PMID:23743303 PMID:12761880 PMID:26330165 |
RGD:2317610, RGD:10398726 |
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
|
IMP |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:16885372 |
RGD:5135487 |
NCBI chr X:100,775,141...100,777,753
Ensembl chr X:100,775,141...100,777,875
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates severity disease_progression |
ISO IMP |
CTD Direct Evidence: marker/mechanism associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human) associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human) associated with lung non-small cell carcinoma; protein:increased expression:lung (human) associated with oral squamous cell carcinoma associated with pancreatic cancer associated with osteosarcoma;protein:increased expression:bone (human) human cells in mouse model;associated with lung cancer associated with lung cancer; human cells in mouse model |
CTD RGD |
PMID:21312072 PMID:23743303 PMID:26546437 PMID:16322285 PMID:18487224 PMID:28000861 PMID:17634424 PMID:16230077 PMID:24932250 PMID:25504108 PMID:32037613 More...
|
RGD:152023746, RGD:152177479, RGD:152177478, RGD:152177476, RGD:152177475, RGD:152025556, RGD:152023745, RGD:152023741, RGD:151708730 |
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28112739 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Dab2ip |
disabled 2 interacting protein |
severity |
ISO |
associated with colorectal cancer;protein:decreased expression:colorectum (human) |
RGD |
PMID:26336990 |
RGD:11531913 |
NCBI chr 2:35,448,285...35,621,006
Ensembl chr 2:35,448,278...35,621,006
|
|
G |
Dapk1 |
death associated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17319784 |
|
NCBI chr13:60,749,506...60,911,005
Ensembl chr13:60,749,761...60,911,005
|
|
G |
Daxx |
Fas death domain-associated protein |
|
ISO |
|
RGD |
PMID:23539629 |
RGD:9587820 |
NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564
|
|
G |
Dcn |
decorin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18688028 |
RGD:2311418 |
NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005
|
|
G |
Ddr1 |
discoidin domain receptor family, member 1 |
severity |
ISO |
mRNA:increased expression:ovary (human) protein:increased expression:bone (human) |
RGD |
PMID:28743276 PMID:29039472 |
RGD:151347541, RGD:151347601 |
NCBI chr17:35,992,459...36,015,633
Ensembl chr17:35,992,459...36,015,513
|
|
G |
Ddr2 |
discoidin domain receptor family, member 2 |
ameliorates |
IAGP |
associated with melanoma; |
RGD |
PMID:24293323 |
RGD:150429711 |
NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331
|
|
G |
Ddx3x |
DEAD box helicase 3, X-linked |
|
ISO |
human cells in mouse model |
RGD |
PMID:26087195 |
RGD:11096798 |
NCBI chr X:13,147,261...13,160,222
Ensembl chr X:13,147,209...13,160,291
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr13:47,238,243...47,261,134
Ensembl chr13:47,238,251...47,259,677
|
|
G |
Dhfr |
dihydrofolate reductase |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:19159907 PMID:8149482 |
RGD:11040442 |
NCBI chr13:92,491,291...92,525,561
Ensembl chr13:92,491,234...92,525,561
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26825960 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dmd |
dystrophin, muscular dystrophy |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chr X:81,858,244...84,248,656
Ensembl chr X:81,992,476...84,249,747
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
|
ISO |
associated with Uterine Cervical Neoplasms; |
RGD |
PMID:22330137 |
RGD:9589117 |
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
treatment |
ISO |
associated with Colonic Neoplasms CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:17611699 PMID:11383214 |
RGD:11251755 |
NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573
|
|
G |
E2f1 |
E2F transcription factor 1 |
severity |
ISO |
protein:increased expression:bone (human) |
RGD |
PMID:29039472 |
RGD:151347601 |
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
E2f8 |
E2F transcription factor 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27683099 |
|
NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344
|
|
G |
Edn1 |
endothelin 1 |
|
IDA |
|
RGD |
PMID:12941866 |
RGD:734914 |
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
|
IMP |
associated with Bladder Neoplasms |
RGD |
PMID:21183790 |
RGD:4892282 |
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 PMID:20562527 |
|
NCBI chr 1:63,215,990...63,219,645
Ensembl chr 1:63,215,984...63,219,645
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332
|
|
G |
Efnb2 |
ephrin B2 |
|
ISO |
associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human) |
RGD |
PMID:25012246 |
RGD:153305948 |
NCBI chr 8:8,667,235...8,711,242
Ensembl chr 8:8,667,434...8,711,242
|
|
G |
Egf |
epidermal growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21942447 PMID:23064031 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17369752 PMID:17575224 PMID:23867902 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Ehmt2 |
euchromatic histone lysine N-methyltransferase 2 |
|
ISO |
associated with lung neoplasms; CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20940408 PMID:25115793 PMID:20940408 |
RGD:9589170 |
NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chr X:158,155,174...158,172,617
Ensembl chr X:158,155,174...158,172,924
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chr16:22,924,846...22,932,882
Ensembl chr16:22,926,194...22,932,886
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chr14:65,767,895...65,830,561
Ensembl chr14:65,767,898...65,830,524
|
|
G |
Eml4 |
echinoderm microtubule associated protein like 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chr17:83,658,341...83,787,790
Ensembl chr17:83,658,360...83,787,790
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26037280 |
|
NCBI chr15:54,702,297...54,816,284
Ensembl chr15:54,702,297...54,816,288
|
|
G |
Epcam |
epithelial cell adhesion molecule |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557
|
|
G |
Epo |
erythropoietin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
rat gene in a mouse model CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:16984552 PMID:11238891 |
RGD:734938 |
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
disease_progression |
ISO |
associated with Prostatic Neoplasms;protein:alternative form associated with lung adenocarcinoma CTD Direct Evidence: marker/mechanism associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus |
CTD RGD |
PMID:28114269 PMID:18559590 PMID:26254096 PMID:17634423 |
RGD:2298500, RGD:126790470, RGD:2289944 |
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
disease_progression |
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:26254096 |
RGD:126790470 |
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
disease_progression |
ISO |
associated with Melanoma CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20801905 PMID:26202595 |
RGD:11252177 |
NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449
|
|
G |
Ercc4 |
excision repair cross-complementing rodent repair deficiency, complementation group 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20372803 |
|
NCBI chr16:12,927,600...12,969,873
Ensembl chr16:12,927,548...12,968,481
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20104649 PMID:35044086 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Etv4 |
ets variant 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chr11:101,660,573...101,677,963
Ensembl chr11:101,660,568...101,676,197
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
|
ISO |
associated with stomach cancer;protein:increased expression:stomach associated with osteosarcoma associated with lung non-small cell carcinoma |
RGD |
PMID:20132185 PMID:26265454 PMID:24097870 |
RGD:126779607, RGD:11532507, RGD:126781716 |
NCBI chr 6:47,507,208...47,613,843
Ensembl chr 6:47,507,073...47,572,275
|
|
G |
Ezr |
ezrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27137931 |
|
NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183
|
|
G |
F2 |
coagulation factor II |
|
ISO |
associated with Carcinoma, Small cell;protein:increased expression:brain |
RGD |
PMID:22065054 |
RGD:6893520 |
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
Fadd |
Fas associated via death domain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16450001 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Fas |
Fas cell surface death receptor |
|
ISO IEP |
associated with Breast Neoplasms;protein:decreased expression:breast associated with Mammary Neoplasms;protein:decreased expression:lung |
RGD |
PMID:17352235 PMID:17918178 |
RGD:2290053, RGD:2290048 |
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression:breast |
RGD |
PMID:17352235 |
RGD:2290053 |
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19917848 |
|
NCBI chr X:58,107,499...58,630,932
Ensembl chr X:58,107,505...58,613,431
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
IMP |
associated with prostate adenocarcinoma |
RGD |
PMID:23576558 |
RGD:13504748 |
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21975929 |
|
NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
|
|
G |
Fn1 |
fibronectin 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model |
RGD |
PMID:27431311 |
RGD:152995400 |
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15626919 |
RGD:2317788 |
NCBI chr 5:142,946,110...142,958,944
Ensembl chr 5:142,946,098...142,958,940
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Gab2 |
growth factor receptor bound protein 2-associated protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chr 7:96,730,958...96,958,158
Ensembl chr 7:96,730,793...96,958,153
|
|
G |
Gdf15 |
growth differentiation factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23996089 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17978847 |
|
NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235
|
|
G |
Gp1ba |
glycoprotein 1b, alpha polypeptide |
|
IMP |
associated with Melanoma, Experimental |
RGD |
PMID:19727118 |
RGD:10450866 |
NCBI chr11:70,529,928...70,534,812
Ensembl chr11:70,529,948...70,532,862
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25482527 |
|
NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649
|
|
G |
Gpi1 |
glucose-6-phosphate isomerase 1 |
|
IMP |
|
RGD |
PMID:20978190 |
RGD:11051956 |
NCBI chr 7:33,900,752...33,929,761
Ensembl chr 7:33,900,755...33,929,761
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23867582 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Habp2 |
hyaluronic acid binding protein 2 |
treatment |
ISO |
associated with Thyroid Neoplasms |
RGD |
PMID:22715430 |
RGD:11353856 |
NCBI chr19:56,275,541...56,309,252
Ensembl chr19:56,275,569...56,309,254
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
disease_progression |
ISO |
DNA:polymorphisms: : +4259T>G (human) |
RGD |
PMID:22472081 |
RGD:7245505 |
NCBI chr11:46,345,758...46,372,082
Ensembl chr11:46,345,762...46,372,082
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
IMP ISO |
associated with Anaphylaxis; CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:34973135 PMID:24619412 |
RGD:9590165 |
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO IEP |
associated with Pancreatic Neoplasms CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Experimental; associated with Melanoma; |
CTD RGD |
PMID:25971889 PMID:11893931 PMID:16459153 PMID:10688652 |
RGD:2317904, RGD:8548625, RGD:8548538 |
NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582
|
|
G |
Hrh2 |
histamine receptor H2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:6224980 |
|
NCBI chr13:54,345,990...54,390,201
Ensembl chr13:54,346,148...54,390,199
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hspa1a |
heat shock protein 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26984758 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Ibsp |
integrin binding sialoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22407340 PMID:24980816 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Pancreatic Neoplasms;protein:increased expression:serum associated with Melanoma, Cutaneous Malignant |
RGD |
PMID:12923961 PMID:10465581 |
RGD:2325163, RGD:8547593 |
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24910342 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Igf1 |
insulin-like growth factor 1 |
|
ISO |
associated with Pancreatic Neoplasms CTD Direct Evidence: marker/mechanism associated with Uveal Melanoma;protein:increased expression:serum: |
CTD RGD |
PMID:18398872 PMID:19375852 PMID:23197685 |
RGD:2317643, RGD:8548834 |
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:16575403 |
RGD:2317645 |
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igf2 |
insulin-like growth factor 2 |
|
IEP |
associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum: |
RGD |
PMID:21859454 |
RGD:5510000 |
NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
ISO |
associated with colorectal cancer;DNA:polymorphisms: |
RGD |
PMID:31320627 |
RGD:150540328 |
NCBI chr11:11,634,970...11,722,930
Ensembl chr11:11,634,980...11,722,926
|
|
G |
Il10 |
interleukin 10 |
|
ISO |
|
RGD |
PMID:16035616 |
RGD:1598627 |
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
protein:increased expression:serum CTD Direct Evidence: marker/mechanism associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human) associated with breast cancer;protein:increased expression:serum |
CTD RGD |
PMID:12748951 PMID:11215816 PMID:19152241 PMID:12209760 |
RGD:4889862, RGD:8655899, RGD:8655866 |
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with melanoma; associated with neuroblastoma. CTD Direct Evidence: therapeutic |
CTD RGD |
PMID:17105418 PMID:8610104 PMID:9362156 PMID:8642346 |
RGD:8663438, RGD:14865005, RGD:14747043 |
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il6 |
interleukin 6 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:21937440 PMID:26101800 PMID:28186964 |
RGD:127229952 |
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itga6 |
integrin alpha 6 |
|
ISO |
|
RGD |
PMID:13130099 |
RGD:1302259 |
NCBI chr 2:71,617,236...71,688,761
Ensembl chr 2:71,575,960...71,688,760
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23562787 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb3 |
integrin beta 3 |
|
IEP ISO |
mRNA, protein:increased expression:lung associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human) |
RGD |
PMID:21107114 PMID:16831169 |
RGD:5037225, RGD:6907406 |
NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302
|
|
G |
Jak2 |
Janus kinase 2 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model |
RGD |
PMID:28186964 |
RGD:127229952 |
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Jup |
junction plakoglobin |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:15619205 |
RGD:2301746 |
NCBI chr11:100,259,682...100,288,639
Ensembl chr11:100,259,784...100,288,589
|
|
G |
Kdm6a |
lysine (K)-specific demethylase 6A |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:brain (human) |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chr X:18,027,101...18,147,061
Ensembl chr X:18,028,814...18,146,175
|
|
G |
Kdr |
kinase insert domain protein receptor |
|
ISO |
associated with Carcinoma, Renal Cell |
RGD |
PMID:17465216 |
RGD:2301757 |
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Kif2c |
kinesin family member 2C |
disease_progression |
ISO |
associated with colorectal cancer |
RGD |
PMID:18506187 |
RGD:27372891 |
NCBI chr 4:117,016,830...117,039,821
Ensembl chr 4:117,016,836...117,039,836
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:16283480 |
RGD:2298668 |
NCBI chr 1:133,249,625...133,257,460
Ensembl chr 1:133,237,565...133,257,460 Ensembl chr 1:133,237,565...133,257,460
|
|
G |
Kmt2b |
lysine (K)-specific methyltransferase 2B |
|
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chr 7:30,268,280...30,288,371
Ensembl chr 7:30,268,283...30,288,151
|
|
G |
Kmt2d |
lysine (K)-specific methyltransferase 2D |
disease_progression |
ISO |
associated with colorectal cancer;DNA:mutations:: |
RGD |
PMID:27875625 |
RGD:155582219 |
NCBI chr15:98,729,550...98,771,958
Ensembl chr15:98,729,550...98,769,085
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
treatment disease_progression |
ISO IEP |
CTD Direct Evidence: marker/mechanism associated with stomach cancer; human cells in mouse model associated with colorectal cancer; DNA:mutation:cds: associated with colorectal cancer;DNA:mutations: : associated with colorectal cancer;DNA:mutation: : associated with Fibrosarcoma;mRNA,protein:decreased expression:: |
CTD RGD |
PMID:8635384 PMID:27431311 PMID:27264476 PMID:26210240 PMID:29032374 PMID:3552201 More...
|
RGD:152995400, RGD:14398751, RGD:11086960, RGD:14398745, RGD:11570402 |
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Krt14 |
keratin 14 |
|
ISO |
mRNA:decreased expression:epithelial cell |
RGD |
PMID:9876218 |
RGD:1600180 |
NCBI chr11:100,093,988...100,098,336
Ensembl chr11:100,093,988...100,098,374
|
|
G |
Krt20 |
keratin 20 |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:10931219 |
RGD:2317676 |
NCBI chr11:99,319,211...99,328,979
Ensembl chr11:99,319,229...99,328,976
|
|
G |
L1cam |
L1 cell adhesion molecule |
treatment |
ISO |
associated with Pancreatic Neoplasms; associated with Lung Neoplasms; |
RGD |
PMID:22095073 PMID:22307136 |
RGD:11570404, RGD:11570503 |
NCBI chr X:72,897,384...72,924,843
Ensembl chr X:72,897,384...72,939,711
|
|
G |
Lamc2 |
laminin, gamma 2 |
|
ISO |
associated with lung adenocarcinoma; |
RGD |
PMID:25591736 |
RGD:11075980 |
NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193
|
|
G |
Lcn2 |
lipocalin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24570342 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Lect2 |
leukocyte cell-derived chemotaxin 2 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:30453282 |
|
NCBI chr13:56,676,772...56,696,373
Ensembl chr13:56,690,277...56,696,315
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
associated with prostate cancer CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:27811057 PMID:27067790 |
RGD:11531513 |
NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
|
|
G |
Lgals3 |
lectin, galactose binding, soluble 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25882088 |
|
NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617
|
|
G |
Llgl2 |
LLGL2 scribble cell polarity complex component |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chr11:115,714,855...115,746,606
Ensembl chr11:115,714,875...115,746,606
|
|
G |
Ly96 |
lymphocyte antigen 96 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chr 1:16,758,680...16,779,829
Ensembl chr 1:16,758,275...16,779,835
|
|
G |
Macc1 |
metastasis associated in colon cancer 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:36008464 PMID:27431311 |
RGD:152995400 |
NCBI chr12:119,354,133...119,430,669
Ensembl chr12:119,278,005...119,433,722
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:24244343 PMID:26735578 PMID:30349115 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,852,706
|
|
G |
Map2k4 |
mitogen-activated protein kinase kinase 4 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human) |
RGD |
PMID:22165133 |
RGD:150429749 |
NCBI chr11:65,579,070...65,679,185
Ensembl chr11:65,579,069...65,679,123
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
treatment |
ISO IDA |
CTD Direct Evidence: marker/mechanism associated with prostate adenocarcinoma |
CTD RGD |
PMID:22580338 PMID:22139534 |
RGD:13504820 |
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
ISO |
CTD Direct Evidence: therapeutic associated with Colorectal Neoplasms |
CTD RGD |
PMID:21779479 PMID:25205654 |
RGD:13217416 |
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Med28 |
mediator complex subunit 28 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21942447 |
|
NCBI chr 5:45,677,571...45,686,626
Ensembl chr 5:45,677,571...45,686,618
|
|
G |
Met |
met proto-oncogene |
disease_progression |
ISO |
associated with Squamous Cell Carcinoma of the Tongue; CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20080979 PMID:21225626 PMID:22704061 |
RGD:8548616 |
NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979
|
|
G |
Mir100 |
microRNA 100 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 9:41,442,721...41,442,800
Ensembl chr 9:41,442,721...41,442,800
|
|
G |
Mir106a |
microRNA 106a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr X:51,831,380...51,831,444
Ensembl chr X:51,831,380...51,831,444
|
|
G |
Mir125a |
microRNA 125a |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with stomach cancer; |
CTD RGD |
PMID:19487542 PMID:30117667 |
RGD:21403678 |
NCBI chr17:18,051,074...18,051,141
Ensembl chr17:18,051,074...18,051,141
|
|
G |
Mir130a |
microRNA 130a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 2:84,571,459...84,571,522
Ensembl chr 2:84,571,459...84,571,522
|
|
G |
Mir130b |
microRNA 130b |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr16:16,941,925...16,942,006
Ensembl chr16:16,941,925...16,942,006
|
|
G |
Mir136 |
microRNA 136 |
ameliorates |
ISO |
associated with stomach cancer;human cells in mouse model |
RGD |
PMID:28656883 |
RGD:153344628 |
NCBI chr12:109,561,761...109,561,822
Ensembl chr12:109,561,761...109,561,822
|
|
G |
Mir148b |
microRNA 148b |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr15:103,193,552...103,193,648
Ensembl chr15:103,193,552...103,193,648
|
|
G |
Mir152 |
microRNA 152 |
|
ISO |
associated with Castration-Resistant Prostatic Neoplasms |
RGD |
PMID:23574937 |
RGD:19165145 |
NCBI chr11:96,741,219...96,741,291
Ensembl chr11:96,741,219...96,741,291
|
|
G |
Mir155 |
microRNA 155 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:19487542 PMID:27692344 PMID:27856635 |
RGD:21079446 |
NCBI chr16:84,511,028...84,511,092
Ensembl chr16:84,511,028...84,511,092
|
|
G |
Mir181c |
microRNA 181c |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 8:84,905,502...84,905,590
Ensembl chr 8:84,905,502...84,905,590
|
|
G |
Mir181d |
microRNA 181d |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 8:84,905,345...84,905,416
Ensembl chr 8:84,905,345...84,905,416
|
|
G |
Mir18b |
microRNA 18b |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr X:51,831,208...51,831,290
Ensembl chr X:51,831,208...51,831,290
|
|
G |
Mir193a |
microRNA 193a |
exacerbates |
ISO |
associated with colorectal cancer; miRNA:decreased expression:colorectum (human) associated with lung non-small cell carcinoma; human cells in mouse model |
RGD |
PMID:25232258 PMID:30685413 PMID:24469061 |
RGD:153344566, RGD:153344599, RGD:153344592 |
NCBI chr11:79,602,795...79,602,860
Ensembl chr11:79,602,795...79,602,860
|
|
G |
Mir19a |
microRNA 19a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr14:115,281,432...115,281,513
Ensembl chr14:115,281,432...115,281,513
|
|
G |
Mir205 |
microRNA 205 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 1:193,189,771...193,189,838
Ensembl chr 1:193,189,771...193,189,838
|
|
G |
Mir20a |
microRNA 20a |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:27286257 |
RGD:25823157 |
NCBI chr14:115,281,589...115,281,695
Ensembl chr14:115,281,589...115,281,695
|
|
G |
Mir20b |
microRNA 20b |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr X:51,830,990...51,831,069
Ensembl chr X:51,830,990...51,831,069
|
|
G |
Mir21a |
microRNA 21a |
treatment ameliorates |
ISO |
associated with prostate carcinoma; human cells in mouse model CTD Direct Evidence: marker/mechanism human cells in mouse model;associated with breast cancer |
CTD RGD |
PMID:26101800 PMID:32736696 PMID:18270520 |
RGD:152998873, RGD:152998897 |
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir221 |
microRNA 221 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr X:19,012,533...19,012,627
Ensembl chr X:19,012,533...19,012,627
|
|
G |
Mir222 |
microRNA 222 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr X:19,013,132...19,013,210
Ensembl chr X:19,013,132...19,013,210
|
|
G |
Mir224 |
microRNA 224 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with colorectal cancer; mRNA:increased expression:colorectal mucosa: |
CTD RGD |
PMID:19487542 PMID:25919696 |
RGD:14398749 |
NCBI chr X:71,304,637...71,304,718
Ensembl chr X:71,304,637...71,304,718
|
|
G |
Mir30a |
microRNA 30a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 1:23,311,350...23,311,420
Ensembl chr 1:23,311,350...23,311,420
|
|
G |
Mir30e |
microRNA 30e |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19487542 |
|
NCBI chr 4:120,629,803...120,629,894
Ensembl chr 4:120,629,803...120,629,894
|
|
G |
Mir31 |
microRNA 31 |
disease_progression treatment |
ISO |
CTD Direct Evidence: marker/mechanism associated with colorectal cancer;RNA:increased expression:colorectum (human) associated with stomach cancer;human cells in mouse model |
CTD RGD |
PMID:19487542 PMID:26497852 PMID:27174918 PMID:30108104 |
RGD:153297806, RGD:153297811, RGD:153297776 |
NCBI chr 4:88,828,794...88,828,899
Ensembl chr 4:88,828,794...88,828,899
|
|
G |
| |